学术周报 · IF≥10
消化内科领域文献阅读汇编
2026年第41周 (2026-10-08) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Gut | 6 | IF 24.6 |
| IEEE transactions on cybernetics | 5 | IF 11.3 |
| Endoscopy | 4 | IF 11.8 |
| Gastroenterology | 4 | IF 29.7 |
| Journal of hepatology | 4 | IF 40.1 |
| Water research | 3 | IF 12.8 |
| Biomaterials | 3 | IF 13.6 |
| Journal of advanced research | 2 | IF 17.1 |
| Drugs | 2 | IF 14.7 |
| MedComm | 2 | IF 14.1 |
1炎症性肠病/IBD (10篇)
临床研究 (2篇)
The PIONIR (Preventing IBD ONset in Individuals at Risk) trial evaluates whether the Tasty&Healthy diet can reduce risk of Crohn's disease (CD) development in first-degree relatives (FDRs). The optimal preclinical stage of CD for enrolling subjects to prevention trials is unknown. We aimed to propose a framework for identifying high-risk participants for prevention trials by reporting the outcomes of the pre-PIONIR screening stage. Faecal calprotectin was measured in asymptomatic FDRs aged 6-38 years; those with persistent elevation, defined as >70 µg/g in at least two separate tests, were offered panenteric video capsule-endoscopy or ileocolonoscopy. Of 950 FDRs approached, 331 (35%) agreed to be screened: 63 (19%) had persistently elevated calprotectin, of whom 42 underwent further evaluation. Nine (2.7%) had endoscopic appearance compatible with presymptomatic CD, 22 (6.6%) had non-specific macroscopic mucosal changes and 11 (3.3%) had normal mucosa despite elevated calprotectin, suggesting probable histological inflammation. The 33 participants in the two latter groups were defined as 'potential pre-CD' (17.9% of all screened after adjusting for missing values). Calprotectin >225 µg/g predicted presymptomatic CD (area under the receiver operating characteristic curve 0.97 (95% CI 0.94 to 1.0; p<0.001; sensitivity 89%, specificity 94%). Of those with a single elevated calprotectin value, 22% normalised on repeat testing with significant variability (intraclass correlation coefficient 0.72 (95% CI 0.57 to 0.82)). Approximately one in five asymptomatic FDRs had persistently elevated calprotectin, which was able to differentiate those with presymptomatic CD. The findings highlight calprotectin's utility in identifying at-risk individuals during the potential pre-CD stage for enrolment in prevention trials.
中文摘要:PIONIR(Preventing IBD ONset in Individuals at Risk)试验评估Tasty&Healthy饮食能否降低一级亲属(FDRs)发生克罗恩病(CD)的风险。对于将受试者纳入预防试验而言,CD的最佳临床前阶段尚不明确。我们旨在通过报告PIONIR前期筛查阶段的结果,提出一个用于识别预防试验高危参与者的框架。对6~38岁无症状FDRs测量粪便钙卫蛋白;对持续升高者,定义为至少两次独立检测>70 µg/g,提供全肠道视频胶囊内镜或回结肠镜检查。在950名被联系的FDRs中,331名(35%)同意接受筛查:63名(19%)钙卫蛋白持续升高,其中42名接受了进一步评估。9名(2.7%)内镜下表现符合症状前CD,22名(6.6%)存在非特异性肉眼黏膜改变,11名(3.3%)尽管钙卫蛋白升高但黏膜正常,提示可能存在组织学炎症。后两组33名参与者被定义为「潜在临床前CD」(在校正缺失值后占所有筛查者的17.9%)。钙卫蛋白>225 µg/g可预测症状前CD(受试者工作特征曲线下面积0.97(95% CI 0.94~1.0;p<0.001;敏感性89%,特异性94%)。在单次钙卫蛋白升高者中,22%在重复检测时恢复正常,且变异性显著(组内相关系数0.72(95% CI 0.57~0.82))。约五分之一无症状FDRs存在钙卫蛋白持续升高,其能够区分症状前CD者。这些发现凸显了钙卫蛋白在潜在临床前CD阶段识别高危个体以纳入预防试验中的效用。
Gene-environment interactions (GxE) are fundamental for understanding the mechanisms of human diseases. Tobacco smoking is of particular interest for Inflammatory bowel disease (IBD), as it worsens Crohn's disease (CD) but protects against ulcerative colitis (UC). Here, we systematically examined the genome-wide genetic modifiers of tobacco smoking and analysed functional smoking-dependent expression quantitative trait loci (eQTL) in IBD intestinal tissues. Multiplicative interaction effects of genetic variants and tobacco smoking were estimated and meta-analysed from two independent cohorts (cohort A, N = 990; cohort B, N = 2540). Subsequent separate analyses were conducted for CD and UC to identify opposite interaction. The association between HLA classical alleles/amino acid residues and smoking status was tested. GxE eQTL analysis was performed by combining IBD genotype and mucosal transcriptome data. Colocalisation analysis was conducted to identify the shared loci across the results from genome-wide interaction meta-analysis and the GxE eQTL analysis. A total of 572 candidate independent lead genetic variants with multiplicative interactions with tobacco smoking regarding IBD risk were prioritised at a suggestive significance level (meta-analysis P < 5.0 × 10-5). Thirty genetic loci exhibited noteworthy opposite interactions between CD and UC, implicated genes such as ANKS1B, C7, and PARD3B. HLA-DRβ1 harboured the greatest number of polymorphic residues associated with current smoking in IBD. Significant decrease of the frequency of Leu156 in HLA-A was only observed in UC former smokers but not in CD (FDR <0.05). 67 smoking-dependent cis-eQTL- eGene pairs were found in IBD affected intestinal tissues. This study deepens the understanding of complex interactions between tobacco smoking and genetic variants for IBD. As a result, it sheds new light on the genetic contribution to the divergent effects of tobacco smoking on CD and UC risk, which might illuminate the future development of genotype-guided primordial preventive strategies in genetically susceptible individuals. JB acknowledges funding from CSC and University Medical Center Groningen top-up Program. EAMF acknowledges funding from ZonMw.
中文摘要:基因-环境交互作用(GxE)是理解人类疾病机制的基础。吸烟与炎症性肠病(IBD)尤为相关,因为吸烟会加重克罗恩病(CD),却对溃疡性结肠炎(UC)具有保护作用。在本研究中,我们系统评估了吸烟的全基因组遗传修饰因素,并分析了IBD肠道组织中具有功能意义的吸烟依赖性表达数量性状位点(eQTL)。我们从两个独立队列(队列A,N=990;队列B,N=2540)中估计了遗传变异与吸烟的相乘交互效应,并进行了荟萃分析。随后分别对CD和UC进行分析,以识别方向相反的交互作用。检测了HLA经典等位基因/氨基酸残基与吸烟状态之间的关联。通过整合IBD基因型和黏膜转录组数据,进行了GxE eQTL分析。进行了共定位分析,以识别全基因组交互荟萃分析与GxE eQTL分析结果之间共享的位点。在提示性显著性水平(荟萃分析P < 5.0 × 10-5)下,共优先筛选出572个与吸烟存在相乘交互作用、且与IBD风险相关的候选独立先导遗传变异。30个遗传位点在CD和UC之间表现出值得注意的方向相反的交互作用,涉及ANKS1B、C7和PARD3B等基因。HLA-DRβ1携带的与IBD当前吸烟状态相关的多态性残基数量最多。HLA-A中Leu156频率的显著降低仅在UC既往吸烟者中观察到,而未在CD中观察到(FDR <0.05)。在IBD受累肠道组织中发现了67对吸烟依赖性顺式eQTL-基因对。本研究加深了对吸烟与遗传变异在IBD中复杂交互作用的理解。因此,该研究为遗传因素如何促成吸烟对CD和UC风险的不同影响提供了新见解,并可能为未来在遗传易感个体中制定基因型指导的原始预防策略提供启示。JB感谢CSC和格罗宁根大学医学中心配套资助项目的资助。EAMF感谢ZonMw的资助。
基础研究 (8篇)
We sensitized mice to different foods (dairy and gluten) after intestinal inflammation (chemically- and hapten-induced models), then mice were re-exposed to the sensitizing foods through diet enrichment. To study whether inflamed microbiota facilitates adverse food reactions, we employed gnotobiotic models and bacterial supplementation experiments. We assessed markers of intestinal inflammation and sensitization, clinical responses, RNA transcripts, and microbiota composition and function. In a translational approach, we recruited IBD patients in remission and healthy controls, recorded self-reported food intolerances and clinical responses to triggering foods, and collected feces for gut microbiota analyses. Intestinal inflammation facilitates food sensitization by disrupting microbial antigen metabolism, recruiting mast cells to the colon, and favoring IgE production. In gnotobiotic models, inflammation-driven depletion of colonic bacteria involved in food digestion contributed to food sensitization. Upon re-exposure to triggering foods, sensitized mice experienced visceral pain and low-grade inflammation through mast-cell mediated mechanisms, which also worsened experimental colitis. Supplementation with depleted bacteria or treatment with mast cell stabilizers attenuated food-driven responses. In IBD patients, self-reported food intolerances were common and associated with microbial disruption and depletion of food-metabolizing bacteria. Microbial metabolism of foods is disrupted after intestinal inflammation. This facilitates food sensitization, through colonic mast cell-mediated immune responses, which may explain the high number of adverse food reactions reported by IBD patients.
中文摘要:我们在肠道炎症(化学诱导和半抗原诱导模型)后使小鼠对不同食物(乳制品和麸质)致敏,随后通过膳食强化使小鼠再次暴露于致敏食物。为研究发炎的微生物群是否促进不良食物反应,我们采用悉生模型和细菌补充实验。我们评估了肠道炎症和致敏标志物、临床反应、RNA转录本以及微生物群组成和功能。在转化研究中,我们招募了缓解期IBD患者和健康对照,记录自我报告的食物不耐受和对触发食物的临床反应,并收集粪便进行肠道微生物群分析。肠道炎症通过破坏微生物对抗原的代谢、将肥大细胞募集至结肠并促进IgE产生,从而促进食物致敏。在悉生模型中,炎症驱动的参与食物消化的结肠细菌耗竭促进了食物致敏。再次暴露于触发食物后,致敏小鼠通过肥大细胞介导的机制出现内脏疼痛和低度炎症,这也加重了实验性结肠炎。补充耗竭的细菌或用肥大细胞稳定剂治疗可减轻食物驱动的反应。在IBD患者中,自我报告的食物不耐受很常见,并与微生物群破坏和食物代谢细菌耗竭相关。肠道炎症后,微生物对食物的代谢被破坏。这通过结肠肥大细胞介导的免疫反应促进食物致敏,可能解释IBD患者报告的大量不良食物反应。
Inflammatory bowel disease (IBD) is typically diagnosed after the onset of symptoms in the context of established, characteristic patterns of intestinal inflammation. However, there is now substantial evidence pointing to a prolonged, biologically active preclinical phase of disease. Analysis of archived biological samples from large-scale longitudinal cohort studies of healthy individuals, some of whom develop incident IBD, has identified different molecular features that can be detected many years before clinical presentation. These include increased titres of antimicrobial and autoreactive antibodies and perturbations in a complex network of circulating, immunologically active proteins. As well as affording 'diagnostic' opportunities to identify individuals destined to develop IBD, an integrated view of these multiple different molecular features enables speculation of potential proximal drivers of preclinical IBD. Consistently recognised associations include dysregulated mononuclear phagocyte-lymphocyte interactions, augmented chemotaxis, frequently relating to interferon-γ-driven chemokine programmes and evidence of early tissue injury, such as increased circulating extracellular matrix components and metalloproteinases. Increased levels of circulating antibacterial and antiviral antibody responses hint towards disordered host-microbe interactions as potential prime triggers for the transition between health and early disease, although it is possible that these serological responses are an epiphenomenon linked to early mucosal damage and microbial translocation. There is now a timely opportunity to develop these different molecular features into scalable and clinically tractable biomarker panels to detect preclinical disease and enable strategies to proactively intercept IBD before it even develops.
中文摘要:炎症性肠病(IBD)通常在症状出现后、并已具备典型肠道炎症模式时才被诊断。然而,目前有大量证据提示该病存在一个持续时间较长、具有生物学活性的临床前期阶段。对大规模纵向队列研究(纳入健康个体,其中部分人日后发生IBD)所留存生物样本的分析,已鉴定出多种可在临床表现出现多年前被检测到的分子特征。这些特征包括抗菌抗体和自身反应性抗体滴度升高,以及循环中具有免疫活性的复杂蛋白网络出现紊乱。除了为识别日后必将发生IBD的个体提供「诊断」机会外,对这些多种不同分子特征进行整合分析,还使人们能够推测临床前期IBD的潜在近端驱动因素。被一致认可的关联包括单核吞噬细胞与淋巴细胞相互作用失调、趋化作用增强(常与干扰素-γ驱动的趋化因子程序相关),以及早期组织损伤的证据,如循环细胞外基质成分和金属蛋白酶升高。循环中抗细菌和抗病毒抗体反应水平升高,提示宿主与微生物之间相互作用紊乱可能是健康向早期疾病转变的潜在始动触发因素,尽管这些血清学反应也可能是与早期黏膜损伤和微生物易位相关的伴随现象。目前正有一个恰逢其时的机会,可将这些不同的分子特征发展为可扩展且临床可行的生物标志物组合,以检测临床前疾病,并制定在IBD真正发生之前即主动拦截其发生的策略。
Proteins containing the broad-complex, tramtrack and bric-à-brac (BTB) domain, also referred to as the poxvirus and zinc finger (POZ) domain, play a variety of cellular roles. As key mediators of protein-protein interactions, these proteins participate in the regulation of various biological processes. In this study, we discovered that ankyrin repeat and BTB domain-containing protein 1 (ABTB1) acts as an important regulator of the differentiation of T helper 17 (Th17) cells. ABTB1 deficiency promotes Th17 cell differentiation and exacerbates the symptoms associated with dextran sodium sulfate (DSS)-induced colitis by enhancing Th17 cell-mediated inflammatory responses. Furthermore, the loss of ABTB1 decreases the polyubiquitination of signal transducer and activator of transcription 3 (STAT3) while increasing both the total expression and phosphorylation levels of the STAT3 protein, which are critical for Th17 cell differentiation. On a mechanistic level, this study provides the first evidence that neddylated ABTB1 functions as a novel E3 ubiquitin ligase. Neddylated ABTB1 mediates the K27-, K33-, and K48-linked polyubiquitination of STAT3, thereby promoting its degradation via the ubiquitin-proteasome pathway. Accordingly, ABTB1 inhibits the excessive activation of STAT3 and ultimately suppresses Th17 cell differentiation. Overall, our research demonstrates the critical role of ABTB1 in regulating the differentiation and function of Th17 cells under conditions of autoimmune diseases. Thus, ABTB1 may represent a potential therapeutic target for inflammatory bowel disease (IBD) and other autoimmune disorders.
中文摘要:含有broad-complex、tramtrack和bric-à-brac(BTB)结构域(也称为痘病毒和锌指(POZ)结构域)的蛋白质在细胞中发挥多种作用。作为蛋白质-蛋白质相互作用的关键介质,这些蛋白质参与调控多种生物学过程。在本研究中,我们发现含锚蛋白重复序列和BTB结构域的蛋白1(ABTB1)是辅助性T细胞17(Th17)分化的一个重要调控因子。ABTB1缺失会促进Th17细胞分化,并通过增强Th17细胞介导的炎症反应加重葡聚糖硫酸钠(DSS)诱导结肠炎的相关症状。此外,ABTB1缺失会降低信号转导与转录激活因子3(STAT3)的多聚泛素化,同时升高STAT3蛋白的总表达和磷酸化水平,而这些对Th17细胞分化至关重要。在机制层面,本研究首次提供证据表明,类泛素化修饰的ABTB1作为一种新型E3泛素连接酶发挥作用。类泛素化修饰的ABTB1介导STAT3的K27、K33和K48连接的多聚泛素化,从而通过泛素-蛋白酶体途径促进其降解。因此,ABTB1抑制STAT3的过度激活,并最终抑制Th17细胞分化。总体而言,我们的研究证明ABTB1在自身免疫性疾病条件下调控Th17细胞的分化和功能中起关键作用。因此,ABTB1可能成为炎症性肠病(IBD)和其他自身免疫性疾病的潜在治疗靶点。
Macrophage-enteric neuron dialog is crucial for intestinal homeostasis, but its specific role and underlying mechanism in inflammatory bowel disease (IBD) pathogenesis remain elusive. Here, we demonstrate that colonic macrophage-mediated extracellular matrix (ECM) remodeling orchestrates enteric neuronal maturation and dictates colitis progression. The depletion of Pcif1, recognized as a unique methyltransferase for m6Am mRNA methylation, in macrophages attenuates colitis and protects enteric neurons from inflammation-driven degeneration. Specifically, Pcif1-deficient macrophages increase ECM accumulation, promoting their own extravasation into enteric neuronal plexuses and the maturation of enteric neurons, thereby curbing inflammation-driven neuronal injury and colitis progression. Mechanistically, Pcif1-mediated m6Am modification inhibits the translation of Znf219 mRNA and represses the Znf219-Egr1 axis, a master transcriptional module that governs ECM remodeling. Finally, pharmacological blockade of PCIF1 promotes macrophage-mediated ECM deposition and suppresses colitis and neuronal loss. Our findings reveal a novel mechanism whereby ECM remodeling in macrophages drives enteric neuronal maturation and illuminate the m6Am machinery as a promising therapeutic target for preventing neuronal loss in IBD patients.
中文摘要:巨噬细胞与肠神经元的对话对肠道稳态至关重要,但其在炎症性肠病(IBD)发病机制中的具体作用及潜在机制仍不明确。在此,我们证明结肠巨噬细胞介导的细胞外基质(ECM)重塑协调肠神经元成熟并决定结肠炎进展。巨噬细胞中Pcif1的缺失(Pcif1被认为是m6Am mRNA甲基化的独特甲基转移酶)可减轻结肠炎并保护肠神经元免受炎症驱动的退变。具体而言,Pcif1缺陷巨噬细胞增加ECM积聚,促进其自身外渗进入肠神经丛以及肠神经元成熟,从而抑制炎症驱动的神经元损伤和结肠炎进展。在机制上,Pcif1介导的m6Am修饰抑制Znf219 mRNA的翻译,并抑制Znf219-Egr1轴,而该轴是控制ECM重塑的主要转录模块。最后,药理学阻断PCIF1可促进巨噬细胞介导的ECM沉积,并抑制结肠炎和神经元丢失。我们的发现揭示了一种新机制,即巨噬细胞中的ECM重塑驱动肠神经元成熟,并阐明m6Am机制作为预防IBD患者神经元丢失的有前景的治疗靶点。
Inflammatory bowel disease (IBD) management necessitates novel, diet-compatible therapeutics. Using untargeted metabolomics, we identified magnoflorine as the key anti-colitis alkaloid from the edible fruit Alpinia oxyphylla. Integrated network pharmacology, molecular docking, and a zebrafish colitis model revealed that magnoflorine directly binds to core targets including SRC and STAT3. In DSS-induced colitis, magnoflorine restored intestinal barrier integrity (upregulating ZO-1, occludin, and mucin) and rebalanced inflammatory responses (suppressing TNF-α and IL-6 while promoting IL-22 and defensin-1). Mechanistically, magnoflorine not only inhibited JAK/STAT3 phosphorylation but also upregulated endogenous negative regulators PTPN6 and PIAS3, revealing a dual-modulatory strategy. These findings establish magnoflorine as a promising diet-derived candidate for IBD, supporting its development as a functional food ingredient.
中文摘要:炎症性肠病(IBD)的管理需要新型且与饮食兼容的治疗方法。利用非靶向代谢组学,我们从可食用果实益智(Alpinia oxyphylla)中鉴定出木兰花碱(magnoflorine)是关键的抗结肠炎生物碱。整合网络药理学、分子对接和斑马鱼结肠炎模型发现,木兰花碱可直接结合包括SRC和STAT3在内的核心靶点。在DSS诱导的结肠炎中,木兰花碱恢复了肠道屏障完整性(上调ZO-1、occludin和黏蛋白),并重新平衡炎症反应(抑制TNF-α和IL-6,同时促进IL-22和防御素-1)。在机制上,木兰花碱不仅抑制JAK/STAT3磷酸化,还上调内源性负调控因子PTPN6和PIAS3,揭示了一种双重调控策略。这些发现表明,木兰花碱是一种有前景的膳食来源IBD候选物,支持其作为功能性食品成分的开发。
Systemic bone loss is a frequent extraintestinal complication of inflammatory bowel disease (IBD) and can continue even when intestinal inflammation is clinically controlled. The steps linking gut inflammation to bone deterioration at distant sites are not fully defined. We found that interleukin-18 (IL-18) links intestinal inflammation to bone loss. In the gut, IL-18 supports mucosal repair and barrier maintenance. When circulating IL-18 remains elevated, it accumulates in bone-associated niches, shifts bone remodeling, and ultimately leads to bone loss. While IL-18 is a protective factor essential for intestinal repair and barrier homeostasis, its sustained systemic elevation leads to pathological accumulation in bone-associated niches, driving aberrant bone remodeling and bone loss. To address this challenge, we developed ExoBIP, a bone-targeted and microenvironment-actuated engineered exosome system. This platform enables site-specific IL-18 neutralization within inflamed bone tissues while preserving the physiological function of IL-18 in the gut. ExoBIP integrates the intrinsic pro-osteogenic properties of bone marrow mesenchymal stem cell derived exosomes with spatiotemporally controlled cytokine blockade, thereby simultaneously suppressing inflammation-driven bone resorption and supporting bone regeneration. In a chronic IBD-associated bone loss model, ExoBIP effectively restores bone mass, improves trabecular microarchitecture, and single-cell RNA sequencing showed that ExoBIP restores the marrow niche by increasing osteogenic cells and reducing inflammatory, cytotoxic CD8+ T cell programs. Collectively, this work establishes IL-18 as an actionable driver of IBD-induced bone loss and introduces a precision nanotherapeutic strategy for treating inflammation-induced skeletal complications, highlighting a generalizable paradigm for distal organ protection in chronic inflammatory diseases.
中文摘要:全身性骨丢失是炎症性肠病(IBD)常见的肠外并发症,即使在肠道炎症获得临床控制后仍可继续进展。连接肠道炎症与远处部位骨损害的环节尚未完全阐明。我们发现白细胞介素-18(IL-18)将肠道炎症与骨丢失联系起来。在肠道中,IL-18支持黏膜修复与屏障维持。当循环IL-18持续升高时,其会在骨相关微环境中蓄积,改变骨重塑,最终导致骨丢失。尽管IL-18是肠道修复和屏障稳态所必需的保护性因子,但其持续的全身性升高会导致其在骨相关微环境中病理性蓄积,驱动异常的骨重塑和骨丢失。为应对这一难题,我们开发了ExoBIP,一种骨靶向且由微环境触发的工程化外泌体系统。该平台能够在发炎的骨组织内实现位点特异性的IL-18中和,同时保留IL-18在肠道中的生理功能。ExoBIP将骨髓间充质干细胞来源外泌体固有的促骨生成特性与时空可控的细胞因子阻断相结合,从而同时抑制炎症驱动的骨吸收并支持骨再生。在慢性IBD相关骨丢失模型中,ExoBIP有效恢复了骨量,改善了骨小梁微结构,单细胞RNA测序显示ExoBIP通过增加成骨细胞、减少炎症性与细胞毒性CD8+ T细胞程序而重塑骨髓微环境。总体而言,本研究确立了IL-18作为IBD诱导骨丢失的可干预驱动因素,并提出了一种用于治疗炎症诱导骨骼并发症的精准纳米治疗策略,凸显了慢性炎症性疾病中远端器官保护的可推广范式。
An elevated risk for inflammatory bowel disease (IBD) has been linked to the intake of high-fat diet (HFD), yet the underlying molecular mechanisms remain unclear. The lysosome and the macroautophagy/autophagy-lysosome pathway (ALP) are critical for maintaining the intestinal epithelial barrier. By employing both an in vivo model of dextran sulfate sodium (DSS)-induced colitis in mice and an in vitro model using lipopolysaccharide (LPS)-treated NCM460 cells, we established that HFD in vivo and palmitic acid (PA) in vitro profoundly impair epithelial barrier function and amplify inflammation, which was linked to the suppression of lysosomal function and the ALP. Mechanistically, HFD in vivo and PA in vitro activated STAT3 (p-STAT3[Y705]) under DSS- and LPS-associated inflammatory stress, respectively. This led to a dual suppression of TFEB: on the one hand, activated STAT3 directly bound to the TFEB promoter to inhibit its transcription; on the other hand, it facilitated the lysosomal recruitment of MTOR and activated MTORC1, which promoted TFEB phosphorylation (p-TFEB[S211]) and hindered its nuclear translocation. This cascade resulted in lysosomal membrane permeabilization (LMP), loss of acidification, and impaired degradative function. Intestinal epithelial-specific knockout of Stat3 or pharmacological activation of TFEB restored lysosomal function, repaired the epithelial barrier, and ameliorated colitis. Conversely, rectal administration of AAV9-shTfeb reversed the protective effects conferred by stat3 knockout. Our study reveals that HFD in vivo and PA in vitro disrupt lysosomal function and the intestinal barrier through the STAT3-TFEB axis, suggesting this signaling pathway as a promising avenue for intervention in diet-associated IBD.Abbreviations: AB-PAS: Alcian blue-periodic acid-Schiff; ALP: autophagy-lysosome pathway; CD: Crohn disease; ChIP: chromatin immunoprecipitation; CLEAR: coordinated lysosomal expression and regulation; DSS: dextran sulfate sodium; HFD: high-fat diet; IBD: inflammatory bowel disease; IF: immunofluorescence; IHC: immunohistochemistry; LAMP: lysosome associated membrane protein; LGALS3/Gal3: galectin 3; LMP: lysosomal membrane permeabilization; LPS: lipopolysaccharide; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; PA: palmitic acid; RRAG: Ras-related GTP binding; RRAG-CA: constitutively active RRAG GTPase; RT-qPCR: reverse transcription quantitative PCR; SQSTM1/p62: sequestosome 1; STAT3: signal transducer and activator of transcription 3; TA1: TFEB activator 1; TEM: transmission electron microscopy; TFEB: transcription factor EB; TJ: tight junction; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling; UC: ulcerative colitis; WB: western blot; WT: wild-type.
中文摘要:高脂饮食(HFD)摄入与炎症性肠病(IBD)风险升高相关,但其潜在分子机制仍不清楚。溶酶体以及巨自噬/自噬-溶酶体途径(ALP)对维持肠上皮屏障至关重要。通过采用小鼠右旋糖酐硫酸钠(DSS)诱导结肠炎的体内模型以及脂多糖(LPS)处理NCM460细胞的体外模型,我们证实体内HFD和体外棕榈酸(PA)会显著损害上皮屏障功能并放大炎症,而这与溶酶体功能和ALP受到抑制有关。在机制上,体内HFD和体外PA分别在DSS和LPS相关炎症应激下激活STAT3(p-STAT3[Y705])。这导致对TFEB的双重抑制:一方面,活化的STAT3直接结合TFEB启动子以抑制其转录;另一方面,它促进MTOR向溶酶体募集并激活MTORC1,从而促进TFEB磷酸化(p-TFEB[S211])并阻碍其核转位。这一级联反应导致溶酶体膜透化(LMP)、酸化丧失以及降解功能受损。肠上皮特异性敲除Stat3或药理学激活TFEB可恢复溶酶体功能、修复上皮屏障并改善结肠炎。相反,经直肠给予AAV9-shTfeb可逆转Stat3敲除所赋予的保护作用。我们的研究表明,体内HFD和体外PA通过STAT3-TFEB轴破坏溶酶体功能和肠道屏障,提示该信号通路是干预饮食相关IBD的一个有前景的方向。缩写:AB-PAS:阿利新蓝-过碘酸雪夫染色;ALP:自噬-溶酶体途径;CD:克罗恩病;ChIP:染色质免疫沉淀;CLEAR:协调性溶酶体表达和调控;DSS:右旋糖酐硫酸钠;HFD:高脂饮食;IBD:炎症性肠病;IF:免疫荧光;IHC:免疫组织化学;LAMP:溶酶体相关膜蛋白;LGALS3/Gal3:半乳糖凝集素3;LMP:溶酶体膜透化;LPS:脂多糖;MAP1LC3/LC3:微管相关蛋白1轻链3;MTOR:雷帕霉素机制靶点激酶;MTORC1:雷帕霉素机制靶点激酶复合物1;PA:棕榈酸;RRAG:Ras相关GTP结合蛋白;RRAG-CA:组成性活化RRAG GTP酶;RT-qPCR:逆转录定量PCR;SQSTM1/p62:螯合体1;STAT3:信号转导与转录激活因子3;TA1:TFEB激活剂1;TEM:透射电子显微镜;TFEB:转录因子EB;TJ:紧密连接;TUNEL:末端脱氧核苷酸转移酶dUTP缺口末端标记;UC:溃疡性结肠炎;WB:蛋白质印迹;WT:野生型。
Intestinal barrier dysfunction underlies inflammatory bowel disease (IBD) and is driven, in part, by pathological crosstalk between macrophages and neutrophils that sustains pro-inflammatory cytokine release and excessive formation of neutrophil extracellular trap (NET). In this study, an oral cascade-responsive nanomedicine, PLBD, was developed to co-deliver the prostaglandin D2 receptor agonist BW245C and the NET scavenger DNase I with precise spatiotemporal control and minimal off-target release. PLBD comprises mucus-penetrating, reactive oxygen species (ROS)-sensitive liposomes (LBD) formulated from DSPE-SeSe-PEG, which co-encapsulate BW245C and DNase I, and a microbiota-degradable pectin shell providing gastrointestinal protection. After oral administration, the pectin coating facilitates colonic accumulation and undergoes microbiota-mediated fermentation, whereas the exposed PEGylated liposomes penetrate the mucus barrier. In the ROS-rich inflammatory microenvironment, cleavage of the Se-Se linker triggers the synchronous release of payloads. Functionally, released BW245C facilitates a functional shift in macrophages toward an anti-inflammatory M2-like state while DNase I degrades dysregulated NETs, interrupting the inflammatory loop. In murine models of intestinal barrier dysfunction, PLBD restores epithelial barrier integrity, reduces bacterial translocation, rebalances gut microbiota, attenuates IBD and systemic inflammation. Together, this work validates macrophage-neutrophil crosstalk as a tractable therapeutic target and provide a safe, orally translatable biomaterials strategy for intestinal barrier repair.
中文摘要:肠道屏障功能障碍是炎症性肠病(IBD)的基础,部分由巨噬细胞与中性粒细胞之间的病理性串扰驱动,这种串扰维持促炎细胞因子释放和中性粒细胞胞外诱捕网(NET)的过度形成。本研究开发了一种口服级联响应型纳米药物PLBD,以精确的时空控制和最小的脱靶释放共同递送前列腺素D2受体激动剂BW245C和NET清除剂DNase I。PLBD由穿透黏液的活性氧(ROS)敏感脂质体(LBD)和可被微生物群降解的果胶外壳组成,前者由DSPE-SeSe-PEG配制并共同包封BW245C和DNase I,后者提供胃肠道保护。口服给药后,果胶包衣促进结肠蓄积并经历微生物群介导的发酵,而暴露的PEG化脂质体穿透黏液屏障。在富含ROS的炎症微环境中,Se-Se连接子的断裂触发有效载荷的同步释放。在功能上,释放的BW245C促进巨噬细胞向抗炎M2样状态功能性转变,而DNase I降解失调的NET,从而中断炎症环路。在肠道屏障功能障碍的小鼠模型中,PLBD恢复上皮屏障完整性,减少细菌易位,重新平衡肠道微生物群,减轻IBD和全身炎症。总之,这项工作验证了巨噬细胞-中性粒细胞串扰是可干预的治疗靶点,并为肠道屏障修复提供了一种安全、可口服转化的生物材料策略。
2肝病/肝硬化 (10篇)
基础研究 (10篇)
This study proposes an integrated deep-learning framework for rapid urban flood hazard mapping and damage prediction from compact rainfall descriptors. A simulation-based reference database linked synthetic rainfall scenarios with grid-based flood-depth maps generated by a validated rainfall-runoff and inundation model and category-specific damage indicators derived from damage assessment. For hazard mapping, a principal component analysis-integrated deep neural network predicted retained component scores and reconstructed full inundation maps through inverse transformation. For damage prediction, two pathways were compared: a hybrid pathway using surrogate-generated inundation maps and a latent-assisted deep neural network using principal component analysis-derived inundation features. Across real rainfall events, refinement reduced the mean root mean square error from 0.11 to approximately 0.09 m and increased the mean Nash-Sutcliffe efficiency from 0.48 to approximately 0.57, although further improvement remains necessary under complex observed conditions. The latent-assisted damage pathway achieved a mean normalized root mean square error of 0.02 and a mean coefficient of determination of 0.86 across ten damage indicators, outperforming the hybrid pathway. Overall, the framework reproduced dominant inundation patterns and provided reliable scenario-level damage estimates, offering a computationally efficient basis for rapid flood assessment and forecast-linked decision support.
中文摘要:本研究提出一个集成的深度学习框架,用于基于紧凑降雨描述符快速开展城市洪水危险性制图与损失预测。一个基于模拟的参考数据库将合成降雨情景与由经验证的降雨-径流与淹没模型生成的网格化洪水深度图以及由损失评估得到的类别特定损失指标相联系。对于危险性制图,采用主成分分析集成的深度神经网络预测保留的成分得分,并通过逆变换重建完整淹没图。对于损失预测,比较了两条路径:使用代理生成淹没图的混合路径,以及使用主成分分析所得淹没特征的潜变量辅助深度神经网络。在真实降雨事件中,改进使均方根误差均值从0.11 m降至约0.09 m,并使平均Nash-Sutcliffe效率从0.48提高至约0.57,尽管在复杂观测条件下仍需进一步改进。潜变量辅助损失路径在十个损失指标上取得平均归一化均方根误差0.02和平均决定系数0.86,优于混合路径。总体而言,该框架重现了主要淹没模式,并提供了可靠的场景级损失估计,为快速洪水评估和与预报关联的决策支持提供了计算高效的基础。
Urban non-point source (NPS) pollution poses a significant threat to water environments, yet modeling its complex dynamics remains constrained by the trade-off between the extensive data requirements of process-based models and the limited interpretability of machine learning approaches. This study introduces the physics-informed wash-off network, a hybrid architecture that embeds the differential equations governing pollutant accumulation and wash-off into a recurrent neural network. Leveraging a tabular event dataset, the model generates continuous pollutographs, achieving improved predictive performance with a Nash-Sutcliffe Efficiency of 0.65 and generalization score of 0.94 compared to five state-of-the-art data-driven baselines, where the highest values were 0.33 and 0.89, respectively. Beyond prediction, the model employs interpretability analysis to identify the non-linear drivers of total suspended solids dynamics. Results reveal a distinct divergence: while land use and imperviousness consistently drive both event mean concentration and first flush intensity, precipitation oppositely affects them. Specifically, heavier rainfall dilutes average concentrations but intensifies the first flush. This opposing relationship explains the negative correlation observed between the two metrics and highlights the limitations of uniform stormwater regulations. Consequently, we propose a differentiated management framework: catchments with high first flush potential are strong candidates for rapid diversion and separation technologies, whereas those with low first flush potential are better suited for volume-based retention strategies. These findings advocate for a paradigm shift from static, volume-based controls to dynamic, quality-based management.
中文摘要:城市非点源(NPS)污染对水环境构成重大威胁,但其复杂动态的建模仍受制于基于过程的模型对大量数据的需求与机器学习方法可解释性有限之间的权衡。本研究提出物理信息冲刷网络,这是一种混合架构,将控制污染物累积与冲刷的微分方程嵌入递归神经网络。利用表格化事件数据集,该模型可生成连续污染过程线,与五个最先进的数据驱动基线相比,预测性能得到提升,纳什-萨特克利夫效率为0.65,泛化得分为0.94,而基线最高值分别为0.33和0.89。除预测外,该模型采用可解释性分析来识别总悬浮固体动态的非线性驱动因素。结果揭示出明显分化:土地利用和不透水性持续驱动事件平均浓度和初期冲刷强度,而降水对二者的影响相反。具体而言,更强的降雨会稀释平均浓度,但会增强初期冲刷。这种相反关系解释了两种指标之间观察到的负相关,并凸显了统一雨水管理法规的局限性。因此,我们提出差异化管理框架:初期冲刷潜力高的集水区非常适合快速截流与分离技术,而初期冲刷潜力低的集水区更适合基于体积的滞蓄策略。这些发现倡导从静态的、基于体积的控制转向动态的、基于质量的管理。
Stormwater biofilters are increasingly implemented as nature-based solutions for mitigating trace-level organic contaminants (TrOCs) in urban stormwater. However, TrOC removal in biofilters is often inconsistent because performance varies with compound-specific properties and rainfall-driven system conditions. Reliable TrOC removal prediction is therefore needed to enhance stormwater management. This study evaluated the feasibility of pollutant-based and sensor-based surrogates for predicting the removal of ten TrOCs in biofilters, using data from 26 rainfall events collected over 1.5 years. Surrogate inputs were combined with general descriptors and molecular fingerprints representing TrOC properties and evaluated using machine-learning algorithms. Tree-based ensemble algorithms paired with molecular fingerprints achieved high predictive accuracy, with validation Nash-Sutcliffe efficiency (NSE) values frequently exceeding 0.85. Reduced pollutant-based surrogate sets retained predictive performance, with median NSE decreasing from approximately 0.91 for the full surrogate set to 0.82 for a single surrogate. Among pollutant-based surrogates, ultraviolet absorbance at 254 nm (UVA254), dissolved oxygen (DO), and total nitrogen (TN) were the strongest individual predictors, achieving median NSE values of 0.90, 0.88, and 0.85, respectively, while their combinations offered reliable performance. Sensor-derived event-level descriptors of oxidation-reduction potential (ORP) and soil moisture in the submerged zone (SZ) emerged as robust sensor-based surrogates. Independent validation using historical-rainfall events further supported the robustness of these surrogates, with SZ_ORP and the UVA254 + DO set achieving NSE > 0.70 and showing strong practical potential. Overall, this work establishes a scalable and cost-effective surrogate-based framework for predicting TrOC removal and supporting performance assessment of stormwater biofilters.
中文摘要:雨水生物滤池正日益作为基于自然的解决方案,用于减轻城市雨水中的痕量有机污染物(TrOCs)。然而,生物滤池对TrOC的去除往往不稳定,因为性能会随化合物特异性性质和降雨驱动的系统条件而变化。因此,需要可靠的TrOC去除预测来加强雨水管理。本研究利用1.5年内收集的26场降雨事件数据,评估了基于污染物和基于传感器的替代指标预测生物滤池中十种TrOC去除的可行性。替代指标输入与代表TrOC性质的一般描述符和分子指纹相结合,并使用机器学习算法进行评估。基于树的集成算法与分子指纹配对取得了高预测精度,验证Nash-Sutcliffe效率(NSE)值常超过0.85。缩减的基于污染物的替代指标集保持了预测性能,中位NSE从完整替代指标集的约0.91降至单一替代指标的0.82。在基于污染物的替代指标中,254 nm紫外吸光度(UVA254)、溶解氧(DO)和总氮(TN)是最强的单个预测因子,中位NSE分别为0.90、0.88和0.85,而它们的组合提供了可靠性能。传感器来源的事件级氧化还原电位(ORP)和淹没区(SZ)土壤水分描述符成为稳健的基于传感器的替代指标。使用历史降雨事件进行的独立验证进一步支持了这些替代指标的稳健性,SZ_ORP和UVA254 + DO组合达到NSE > 0.70,并显示出强大的实际潜力。总体而言,这项工作建立了一个可扩展且成本有效的基于替代指标的框架,用于预测TrOC去除并支持雨水生物滤池的性能评估。
This article studies privacy-preserving distributed Nash equilibrium (NE) seeking for aggregative games over directed graphs, where agents' cost functions contain sensitive information. A novel differentially private algorithm using decaying Laplace noise is developed to address two key issues: 1) how to design a distributed algorithm over directed graphs that achieves linear convergence while satisfying differential privacy requirements and 2) how to characterize the tradeoff between convergence accuracy and the privacy budget. First, sufficient conditions for linear convergence are established through the appropriate design of constant step sizes and convex combination parameters. Second, the differential privacy properties of the algorithm are analyzed without assuming bounded gradients, and a quantitative relationship between convergence accuracy and privacy budget is characterized. Furthermore, under additional restrictions on adjacent functions, the cumulative privacy budget admits an explicit expression and remains finite over an unbounded horizon, while the proposed algorithm is proven to converge to the exact NE. Finally, the effectiveness of the proposed algorithm is validated through a Nash-Cournot game and comparative simulations, which demonstrate its superior convergence performance compared to existing methods.
中文摘要:本文研究了有向图上聚合博弈的隐私保护分布式纳什均衡(NE)寻求问题,其中智能体的成本函数包含敏感信息。提出了一种使用衰减拉普拉斯噪声的新型差分隐私算法,以解决两个关键问题:1)如何设计一种在有向图上实现线性收敛同时满足差分隐私要求的分布式算法;2)如何刻画收敛精度与隐私预算之间的权衡。首先,通过适当设计恒定步长和凸组合参数,建立了线性收敛的充分条件。其次,在不假设梯度有界的情况下分析了算法的差分隐私性质,并刻画了收敛精度与隐私预算之间的定量关系。此外,在对相邻函数附加限制下,累积隐私预算具有显式表达式,并在无界时域内保持有限,同时证明所提算法收敛到精确NE。最后,通过纳什-古诺博弈和对比仿真验证了所提算法的有效性,仿真结果表明其收敛性能优于现有方法。
Safety, as a fundamental requirement in human-robot interaction, imposes high demands on autonomous decision-making. Existing studies often model such interaction as a perfect rational game with full observability, ignoring variation in rationality and perceptual constraints. To address these limitations, this article formulates the safe human-robot interaction as a partially observable system with bounded rationality and adopts the cognitive hierarchy (CH) model to characterize the interaction process. However, partial observability leads to discontinuous evolution of game states, resulting in a nonstandard differential game and causing difficulties for theoretical analysis. Based on hybrid system theory and the CH model, this work establishes a relationship between bounded rationality policies and Nash equilibrium, and provides interpretability for integrating CH with reinforcement learning. To further enhance safety, an adaptive low-conservative backward reachability analysis is introduced. Simulation experiments and evaluations on real-world traffic data validate the effectiveness, safety, efficiency, robustness, and predictive accuracy of our framework, reducing conservatism by more than 70% while causing negligible increases in collision risk and achieving approximately 18% higher prediction accuracy compared to another nonequilibrium game model, the level- $k$ model. Furthermore, compared with multiagent reinforcement learning and inverse reinforcement learning (IRL), our framework achieves a better balance between safety and efficiency.
中文摘要:安全作为人-机器人交互中的基本要求,对自主决策提出了很高要求。现有研究常将此类交互建模为完全可观测的完美理性博弈,忽视了理性程度变化和感知约束。为克服这些局限,本文将安全的人-机器人交互表述为具有有限理性的部分可观测系统,并采用认知层级(CH)模型来刻画交互过程。然而,部分可观测性会导致博弈状态的不连续演化,形成非标准微分博弈,给理论分析带来困难。基于混合系统理论和CH模型,本工作建立了有限理性策略与纳什均衡之间的关系,并为将CH与强化学习相结合提供了可解释性。为进一步提升安全性,引入了一种自适应低保守后向可达性分析。仿真实验以及在真实交通数据上的评估验证了该框架的有效性、安全性、效率、鲁棒性和预测准确性,在碰撞风险增加可忽略的情况下将保守性降低超过70%,并且与另一种非均衡博弈模型level-$k$模型相比,预测准确率提高约18%。此外,与多智能体强化学习和逆强化学习(IRL)相比,我们的框架在安全性与效率之间实现了更好的平衡。
Noncooperative Model Predictive Game for Uncertain Multiagent Systems: A Dual-Mode Control Strategy.
This article investigates the dual-mode distributed model predictive control (DMPC) problem for multiagent systems (MASs) in the context of noncooperative games. With regard to the mutual influence of neighbor agents, a novel objective function is developed. It consists of three main parts: the conventional quadratic function of MPC accounting for model performance and control cost, the difference between the local agent and its neighbors to guarantee the consensus, and the neighbor's disturbance to obtain the anti-interference capability. To find a nice balance between the online computational burden, practical feasibility, and model performance, a dual-model control strategy is proposed. Then, to handle the couplings resulting from the agents' communication and the negative influence caused by neighbors, the quadratic boundedness lemma, Rayleigh-Ritz theorem, and slack matrix technique are employed, and therefore, both online and offline problems with solvability are readily established. Additionally, sufficient conditions are provided for the guarantee of stability, and an iterative DMPC-based algorithm is designed to ensure that all the agents reach the $\varepsilon $ -Nash equilibrium ( $\varepsilon $ -NE). Finally, a simulation example of a spacecraft system is presented to validate the effectiveness of the proposed dual-mode DMPC, demonstrating that the spacecraft system can converge to the $\varepsilon $ -NE in a distributed manner.
中文摘要:本文研究非合作博弈背景下多智能体系统(MASs)的双模式分布式模型预测控制(DMPC)问题。考虑邻居智能体之间的相互影响,提出了一种新的目标函数。它由三个主要部分组成:考虑模型性能与控制成本的常规MPC二次函数,为保证一致性而引入的本地智能体与其邻居之间的差异,以及为获得抗干扰能力而考虑的邻居扰动。为在在线计算负担、实际可行性与模型性能之间取得良好平衡,提出了一种双模型控制策略。随后,为处理智能体通信产生的耦合以及邻居带来的负面影响,采用了二次有界性引理、Rayleigh-Ritz定理和松弛矩阵技术,从而容易地建立了具有可解性的在线和离线问题。此外,给出了保证稳定性的充分条件,并设计了一种基于迭代DMPC的算法,以确保所有智能体达到ε-纳什均衡(ε-NE)。最后,给出了一个航天器系统的仿真算例,以验证所提出的双模式DMPC的有效性,表明该航天器系统能够以分布式方式收敛到ε-NE。
This article presents an inverse reinforcement learning (RL) $H_{\infty } $ optimal control approach for a Takagi-Sugeno (T-S) fuzzy system (learner system) with disturbances. To reconstruct the expert system's cost function and imitate the expert system's behavior, a learner-expert framework and two inverse RL algorithms are proposed for the cases of the learner system's dynamics being known and unknown. The two developed learning algorithms are composed of three stages: an optimal control policy update stage, a gradient descent correction stage, and an inverse optimal control iteration stage. The first stage is to update the learner's optimal policies via game algebraic Riccati equations (GAREs), the second stage is to obtain the correction factor by observing the expert system's demonstrated trajectory, and the third stage is to adjust the state-penalty matrix. It is proven that the presented two algorithms are convergent, and the presented fuzzy inverse RL optimal control methodology can ensure the controlled system is asymptotically stable and achieve a Nash equilibrium solution. Finally, the presented fuzzy $H_{\infty } $ optimal control method is applied to an autonomous surface vehicle (ASV) system; the computer simulation and results illustrated the effectiveness of the developed methodology.
中文摘要:本文提出了一种针对带有扰动的 Takagi-Sugeno(T-S)模糊系统(学习器系统)的逆强化学习(RL)H∞ 最优控制方法。为了重构专家系统的代价函数并模仿专家系统的行为,针对学习器系统动力学已知和未知两种情况,提出了一个学习器-专家框架和两种逆强化学习算法。所提出的两种学习算法由三个阶段组成:最优控制策略更新阶段、梯度下降校正阶段和逆最优控制迭代阶段。第一阶段通过博弈代数 Riccati 方程(GAREs)更新学习器的最优策略,第二阶段通过观测专家系统给出的轨迹获得校正因子,第三阶段调整状态惩罚矩阵。证明了所提出的两种算法是收敛的,并且所提出的模糊逆强化学习最优控制方法能够确保受控系统渐近稳定并达到 Nash 均衡解。最后,将所提出的模糊 H∞ 最优控制方法应用于自主水面航行器(ASV)系统;计算机仿真及结果说明了所提出方法的有效性。
In task-oriented applications of multiple omnidirectional mobile redundant manipulators (MOMRMs), effectively utilizing kinematic redundancy is essential for enhancing system performance while ensuring accurate task execution. However, most existing distributed control schemes overlook the influence of communication noise on cooperative behaviors, which consequently undermines system robustness and coordination efficiency. Meanwhile, joint drift remains a long-standing issue in repetitive motion tasks, further affecting system stability and motion consistency. To address these challenges, a hybrid multiobjective optimization framework is developed that integrates orthogonal repetitive motion planning with joint velocity optimization, and an anti-disturbance distributed cooperative control strategy based on game theory is introduced to suppress communication noise and enable independent neighborhood decision-making. To compute for distributed strategies, a fuzzy adaptive dual-input double-integral noise-resistant neural dynamics (FADINRND) model is proposed to approximate Nash equilibria. Different from existing neurodynamic solvers with limited noise-rejection capability, the proposed model suppresses challenging linear and quadratic disturbances, thereby improving convergence rate and system robustness. The convergence and stability of the proposed model are rigorously proven theoretically. The effectiveness and superiority of the scheme and model are verified through numerical simulation and platform experiments.
中文摘要:在面向任务的多全向移动冗余机械臂(MOMRMs)应用中,有效利用运动学冗余对于在确保精确任务执行的同时提升系统性能至关重要。然而,大多数现有分布式控制方案忽视了通信噪声对协作行为的影响,从而削弱了系统鲁棒性和协调效率。同时,关节漂移仍是重复运动任务中长期存在的问题,进一步影响系统稳定性和运动一致性。为应对这些挑战,提出了一种混合多目标优化框架,将正交重复运动规划与关节速度优化相结合,并引入了一种基于博弈论的抗干扰分布式协同控制策略,以抑制通信噪声并实现独立的邻域决策。为求解分布式策略,提出了一种模糊自适应双输入双积分抗噪神经动力学(FADINRND)模型,用于逼近纳什均衡。与现有噪声抑制能力有限的神经动力学求解器不同,所提模型能够抑制具有挑战性的线性和二次扰动,从而提高收敛速度和系统鲁棒性。该模型的收敛性和稳定性得到了严格的理论证明。通过数值仿真和平台实验验证了所提方案和模型的有效性与优越性。
Feature representation learning in graph neural networks (GNNs) is a dynamic process driven by progressive information exchange throughout the graph. Current GNNs typically apply pre-defined message-passing heuristics uniformly across all graph data, even when the assumed relational inductive bias conflicts with the intrinsic graph properties (e.g., heterophily). This limitation hinders a principled understanding of graph learning and motivates a shift from application-specific architectures toward a generalizable paradigm. In this work, we conceptualize GNN learning through the lens of mean-field control, where the desired learning outcome corresponds to a variational critical point, each node reaches a representation that is adaptively calibrated to both itself and the entire graph. Building on this formulation, we propose a mathematical framework based on mean-field control (MFC) to adaptively design GNNs for unseen graph data. Specifically, we jointly optimize two control patterns: diffusive mobility, governing information propagation across the graph, and reactive mobility, regulating feature transformation at individual nodes. Both controls are learned from each input instance by solving an MFC variational problem through Hamiltonian flows characterized by partial differential equations (PDEs). Our variational framework unifies existing PDE-based GNNs as special mean-field control problems with fixed control patterns, and yields an end-to-end deep model, termed Nash-GNN. Extensive experiments show that Nash-GNN achieves state-of-the-art performance across diverse benchmarks, including heterophilic graphs and human connectomes. Beyond empirical gains, the MFC framework offers a principled lens to examine the mechanisms of graph representation learning through collective dynamics, opening promising directions for next-generation GNN design.
中文摘要:图神经网络中的特征表示学习是一个动态过程,由整个图上逐步的信息交换驱动。当前GNN通常对所有图数据统一应用预定义的消息传递启发式方法,即使所假设的关系归纳偏置与图的内在性质(例如异质性)相冲突。这一局限阻碍了对图学习的原理性理解,并促使人们从特定应用架构转向一种可泛化的范式。在本工作中,我们通过平均场控制的视角来构思GNN学习,其中期望的学习结果对应于一个变分临界点,每个节点达到一个能自适应地校准自身与整个图的表示。基于这一表述,我们提出一个基于平均场控制(MFC)的数学框架,以针对未见图数据自适应地设计GNN。具体而言,我们联合优化两种控制模式:扩散迁移性,支配信息在图上的传播;反应迁移性,调节单个节点上的特征变换。两种控制均通过求解由偏微分方程(PDE)刻画、经由哈密顿流实现的MFC变分问题,从每个输入实例中学习得到。我们的变分框架将现有基于PDE的GNN统一为具有固定控制模式的特例平均场控制问题,并得到一个端到端深度模型,称为Nash-GNN。大量实验表明,Nash-GNN在包括异质图和人脑连接组在内的多种基准上达到最先进性能。除实证收益外,MFC框架提供了一种原理性视角,通过集体动力学考察图表示学习的机制,为下一代GNN设计开辟了有前景的方向。
The primary challenge in deploying Large Language Model (LLM) is ensuring its harmlessness. Red team can identify vulnerabilities by attacking LLM to attain safety. However, current efforts heavily rely on single-round prompt designs and unilateral red team optimizations against fixed blue teams. These static approaches lead to significant reductions in generation diversity, known as the mode collapse, which makes it difficult to discover the potential risks in the increasingly complex human-LLM interactions. Here we introduce dynamic Red Team Game (RTG) to comprehensively analyze the multi-round offensive and defensive interactions between red team and blue team. Furthermore, we develop a Gamified Red Team Solver (GRTS) with diversity measures to mitigate mode collapse and theoretically guarantee the convergence of approximate Nash equilibrium which results in better strategies for both teams. Empirical results demonstrate that GRTS explore diverse and implicit attacks to adaptively exploit various LLMs, surpassing the constraints of specific modes. Insightfully, the geometrical structure we unveil of the red team task aligns with the spinning top hypothesis, confirming the necessity of constructing a diverse LLM population as a promising proxy for heterogeneous human expert red-teamers. This paves the way for scalable toxicity detection and safe alignment for LLMs.
中文摘要:部署大语言模型(LLM)的首要挑战是确保其无害性。红队可以通过攻击LLM来识别漏洞,从而提升安全性。然而,当前工作严重依赖单轮提示设计,以及针对固定蓝队的单方面红队优化。这些静态方法会导致生成多样性显著下降,即所谓的模式崩溃,使得在日益复杂的人与LLM交互中难以发现潜在风险。在此,我们引入动态红队博弈(RTG),以全面分析红队与蓝队之间的多轮攻防交互。此外,我们开发了带有多样性度量的游戏化红队求解器(GRTS),以缓解模式崩溃,并在理论上保证近似纳什均衡的收敛,从而为双方获得更优策略。实证结果表明,GRTS能够探索多样且隐式的攻击,以自适应地利用各种LLM,超越特定模式的限制。具有启发性的是,我们揭示的红队任务几何结构与陀螺假说相一致,证实构建多样化LLM群体作为异质人类专家红队成员的有前景替代方案的必要性。这为可扩展的毒性检测和LLM安全对齐开辟了道路。
3胰腺炎 (6篇)
临床研究 (1篇)
Post-ERCP pancreatitis (PEP) remains the most frequent adverse event after ERCP. Although rectal NSAIDs and aggressive intravenous hydration are guideline-endorsed, the incremental benefit of adding hydration to NSAIDs is uncertain. We performed a meta-analysis of randomized controlled trials (RCTs) comparing NSAIDs plus aggressive hydration versus NSAIDs alone for PEP prevention. A systematic search in MEDLINE, Scopus, and Cochrane Library databases was performed for RCTs comparing NSAIDs plus aggressive hydration versus NSAIDs alone in adults undergoing ERCP. For the primary outcome a random-effects meta-analysis was conducted to estimate the PEP pooled risk ratios (RRs) with 95% CIs. Supplementary analyses included pooled arm-specific PEP incidence, sensitivity analyses for few trials and sparse events, and trial sequential analysis (TSA). Eight RCTs with a total of 1,903 patients were included. The pooled arm-specific incidence of PEP was 2.8% (95% CI 0.4%-6.7%) with NSAIDs plus aggressive hydration and 7.6% (95% CI 5.2%-10.4%) with NSAIDs alone.. The DerSimonian-Laird random-effects analysis suggested a directionally favorable but statistically inconclusive estimate with combination prophylaxis (RR 0.66, 95% CI 0.40-1.08; I²=18%),whereas the pooled risk difference was -3.8% (95% CI -6.3 to -1.4). . The REML/Hartung-Knapp analysis was also inconclusive (RR 0.73, 95% CI 0.45-1.18). Trial sequential analysis showed that the required information size (RIS) had not been reached. Compared with NSAIDs alone, the addition of aggressive hydration resulted in a directionally lower but statistically inconclusive relative risk of PEP. Although the pooled risk difference favored combination therapy, the small-sample-robust and trial-sequential analyses remained inconclusive. The available evidence therefore does not establish superiority.
中文摘要:ERCP术后胰腺炎(PEP)仍是ERCP后最常见的不良事件。尽管直肠NSAIDs和积极静脉补液均获指南推荐,但在NSAIDs基础上加用补液是否带来额外获益尚不确定。我们开展了一项随机对照试验(RCT)的荟萃分析,比较NSAIDs联合积极补液与单用NSAIDs预防PEP的效果。我们在MEDLINE、Scopus和Cochrane Library数据库中进行了系统检索,纳入在接受ERCP的成人中比较NSAIDs联合积极补液与单用NSAIDs的RCT。对于主要结局,采用随机效应荟萃分析估计PEP的合并风险比(RR)及95%CI。补充分析包括各臂PEP发生率的合并估计、针对试验数量少和事件稀疏的敏感性分析以及试验序贯分析(TSA)。共纳入8项RCT,合计1,903例患者。NSAIDs联合积极补液组的PEP合并各臂发生率为2.8%(95%CI 0.4%-6.7%),单用NSAIDs组为7.6%(95%CI 5.2%-10.4%)。DerSimonian-Laird随机效应分析提示联合预防呈方向性有利但统计学上不确定的估计(RR 0.66,95%CI 0.40-1.08;I²=18%),而合并风险差为-3.8%(95%CI -6.3至-1.4)。REML/Hartung-Knapp分析同样不确定(RR 0.73,95%CI 0.45-1.18)。试验序贯分析显示尚未达到所需信息量(RIS)。与单用NSAIDs相比,加用积极补液导致PEP相对风险在方向上更低,但统计学上不确定。尽管合并风险差支持联合治疗,但小样本稳健分析和试验序贯分析仍不确定。因此,现有证据未能确立其优效性。
基础研究 (5篇)
Hypertriglyceridaemia-induced acute pancreatitis (HTG-AP) is frequently complicated by acute lung injury (ALI), which worsens prognosis. Oleic acid (OA), a major circulating free fatty acid, may play a key role, but the underlying mechanism remains unclear. To investigate the relationship between plasma OA and HTG-AP-associated ALI and to explore the mechanism by which OA disrupts endothelial barrier through PIEZO1-mediated impairment of fatty acid oxidation (FAO). This study used clinical sample analysis, an HTG-AP mouse model and OA-stimulated human umbilical vein endothelial cells. The association between OA and ALI was evaluated, and PIEZO1 was identified as a potential OA target through calcium imaging, transcriptomics and the Human Protein Atlas. Genetic/pharmacological interventions, lipidomics, Seahorse assays and barrier function tests were used to characterise FAO impairment and barrier disruption. NR4A1 regulation of CPT1A was investigated through transcriptomic and ChIP assays. Finally, the pathway's function was validated in mice with endothelial-specific Piezo1 knockdown. Clinical and animal data showed elevated plasma OA in HTG-AP, positively associated with ALI incidence and severity. Multidimensional data identified PIEZO1 as a key target mediating OA-induced endothelial dysfunction. Mechanistically, OA activated and upregulated PIEZO1, which suppressed NR4A1 expression, leading to downregulation of CPT1A and impaired FAO, ultimately disrupting the endothelial barrier. Endothelial-specific Piezo1 knockdown significantly alleviated HTG-AP-associated ALI in mice. OA promotes endothelial barrier dysfunction and exacerbates HTG-AP-associated ALI via the Piezo1/NR4A1/CPT1A axis by impairing FAO, offering a novel mechanistic insight and identifying potential therapeutic targets for HTG-AP-associated ALI.
中文摘要:高甘油三酯血症诱导的急性胰腺炎(HTG-AP)常并发急性肺损伤(ALI),使预后恶化。油酸(OA)是循环中主要的游离脂肪酸,可能起关键作用,但其潜在机制尚不清楚。旨在探讨血浆OA与HTG-AP相关ALI的关系,并探究OA通过PIEZO1介导的脂肪酸氧化(FAO)受损破坏内皮屏障的机制。本研究采用临床样本分析、HTG-AP小鼠模型和OA刺激的人脐静脉内皮细胞。评估OA与ALI的关联,并通过钙成像、转录组学和人蛋白图谱将PIEZO1鉴定为OA的潜在靶点。采用遗传/药理学干预、脂质组学、Seahorse检测和屏障功能测试来表征FAO受损和屏障破坏。通过转录组学和ChIP检测研究NR4A1对CPT1A的调控。最后,在内皮特异性Piezo1敲低小鼠中验证该通路的功能。临床和动物数据显示HTG-AP中血浆OA升高,与ALI发生率和严重程度正相关。多维数据表明PIEZO1是介导OA诱导内皮功能障碍的关键靶点。机制上,OA激活并上调PIEZO1,抑制NR4A1表达,导致CPT1A下调和FAO受损,最终破坏内皮屏障。内皮特异性Piezo1敲低可显著减轻小鼠HTG-AP相关ALI。OA通过Piezo1/NR4A1/CPT1A轴损害FAO,促进内皮屏障功能障碍并加重HTG-AP相关ALI,提供了新的机制见解,并确定了HTG-AP相关ALI的潜在治疗靶点。
Pancreatitis is a complex inflammatory condition of the pancreas and can be classified into acute pancreatitis (AP) and chronic pancreatitis (CP). The pathogenesis of the disease remains unclear, and effective preventive or therapeutic strategies are currently lacking. Non-coding RNA (ncRNA) regulatory networks consist primarily of miRNAs, lncRNAs, and circRNAs, which precisely regulate gene expression through complex interactions and play a key role in fibrosis and inflammation. In terms of AP, ncRNAs could modulate the activity of pancreatic acinar cells, autophagic flux, inflammatory cell infiltration and the integrity of the intestinal mucosal barrier, which regulates local pancreatic and systemic inflammation. During the progression of CP, ncRNAs mediate the pancreatic persistent inflammation and collagen deposition by regulating the interactions between pancreatic stellate cells and immune cells. ncRNAs serve as promising non-invasive biomarkers for pancreatitis, enabling early diagnosis, severity stratification, complication prediction and differential diagnosis between CP and pancreatic cancer. Therapeutically, ncRNAs represent potential precision intervention targets due to their high regulatability and specificity, although ncRNA-based therapies currently remain at the preclinical stage. Key challenges such as delivery efficiency and targeting specificity must be addressed to facilitate clinical translation. Overall, ncRNAs offer a novel avenue for improving the clinical management of pancreatitis.
中文摘要:胰腺炎是胰腺的一种复杂炎症性疾病,可分为急性胰腺炎(AP)和慢性胰腺炎(CP)。该病的发病机制仍不明确,目前也缺乏有效的预防或治疗策略。非编码RNA(ncRNA)调控网络主要由miRNA、lncRNA和circRNA组成,它们通过复杂的相互作用精确调控基因表达,在纤维化和炎症中发挥关键作用。在AP方面,ncRNA可调节胰腺腺泡细胞的活性、自噬流、炎症细胞浸润以及肠黏膜屏障的完整性,从而调控胰腺局部炎症与全身炎症。在CP进展过程中,ncRNA通过调节胰腺星状细胞与免疫细胞之间的相互作用,介导胰腺持续性炎症与胶原沉积。ncRNA可作为胰腺炎有前景的无创生物标志物,用于早期诊断、严重程度分层、并发症预测以及CP与胰腺癌的鉴别诊断。在治疗方面,由于具有高度的可调控性和特异性,ncRNA是有潜力的精准干预靶点,尽管基于ncRNA的疗法目前仍处于临床前阶段。递送效率和靶向特异性等关键挑战尚待解决,以推动其临床转化。总体而言,ncRNA为改善胰腺炎的临床管理提供了新的途径。
The NADPH oxidase (NOX) enzymes are major sources of reactive oxygen species (ROS) involved in redox signaling and inflammation. However, the specific contribution of individual NOX isoforms to the pathophysiology of acute pancreatitis remains unclear. Here, we investigated the roles of NOX1 and NOX2 in ROS generation in vivo during experimental acute pancreatitis in mice as well as their impact on the regulation of the inflammatory cascade. We confirmed NOX1 expression in the exocrine compartment of the pancreas where it acts as the early and primary source of superoxide in acute pancreatitis. However, both NOX1 and DUOX were expressed in infiltrating neutrophils, suggesting disease-associated reprogramming of these cells within the inflamed pancreas. NOX1 deficiency largely restrained immune cell recruitment, whereas the absence of NOX2 resulted in marked upregulation of pro-inflammatory cytokines tumor necrosis factor-α, interleukin-1β, and interleukin 6, reduced protein phosphatase 2A (PP2A) levels, and enhanced MAPK signaling. In addition, pancreatitis in obese mice induced decreased NOX2 expression in pancreatic macrophages, together with an impaired phagocytic profile in both macrophages and neutrophils. In conclusion, our findings reveal opposing roles of NOX1 and NOX2 in acute pancreatitis, with NOX1 promoting neutrophil recruitment and their inflammation-dependent reprogramming, whereas NOX2 restrains the inflammatory response through PP2A.
中文摘要:NADPH氧化酶(NOX)是活性氧(ROS)的主要来源,参与氧化还原信号传导和炎症。然而,单个NOX亚型对急性胰腺炎病理生理的具体贡献仍不清楚。在此,我们研究了NOX1和NOX2在小鼠实验性急性胰腺炎体内ROS生成中的作用,以及它们对炎症级联调控的影响。我们证实NOX1在胰腺外分泌区表达,并在急性胰腺炎中作为超氧物的早期和主要来源。然而,NOX1和DUOX均在浸润的中性粒细胞中表达,提示这些细胞在炎症胰腺内发生了疾病相关重编程。NOX1缺陷在很大程度上抑制了免疫细胞募集,而NOX2缺失则导致促炎细胞因子肿瘤坏死因子-α、白细胞介素-1β和白细胞介素6显著上调,蛋白磷酸酶2A(PP2A)水平降低,并增强了MAPK信号传导。此外,肥胖小鼠的胰腺炎诱导胰腺巨噬细胞中NOX2表达降低,同时巨噬细胞和中性粒细胞的吞噬功能谱受损。总之,我们的研究结果揭示了NOX1和NOX2在急性胰腺炎中的相反作用,其中NOX1促进中性粒细胞募集及其炎症依赖性重编程,而NOX2通过PP2A抑制炎症反应。
Pancreatitis is influenced by environmental and genetic factors. Genome-wide association studies identified polymorphisms at the X-linked CLDN2 locus as risk factors for chronic pancreatitis. CLDN2 encodes claudin-2 (CLDN2), a paracellular cation-selective channel at tight junctions. However, its role in pancreatitis susceptibility remains unclear. We aimed to determine the role of CLDN2 in pancreatitis onset and progression. Human pancreatic tissue, pancreatitis mouse models, pancreatic ductal epithelial organoids, and isolated mouse pancreatic ducts were used. CLDN2 expression, its regulation by cytokines, and its impact on pancreatic inflammation, fibrosis, and ductal fluid transport were assessed. CLDN2 was up-regulated in human chronic pancreatitis and in both caerulein-induced and T7D23A mutation mouse models. Interferon-γ increased CLDN2 expression at RNA and protein levels in organoids and mouse pancreas. Ifng knockout (KO) mice showed reduced caerulein-induced CLDN2 up-regulation compared with wild-type mice. Functionally, Cldn2 KO mice developed more severe disease in both short-term caerulein treatment-induced acute pancreatitis and in a caerulein- and alcohol-treatment induced chronic pancreatitis models. Organoid-based studies revealed CLDN2 is essential for sodium-dependent water transport and adenosine 3',5'-cyclic monophosphate-driven, cystic fibrosis transmembrane conductance regulator-dependent, and 4,4'-diisothiocyano-2,2'-stilbenedisulfonic acid-sensitive fluid secretion. Finally, studies using isolated pancreatic ducts revealed that forskolin-stimulated fluid secretion requires CLDN2. These findings suggest that functional cross talk between paracellular CLDN2 and transcellular transporters is essential for fluid secretion in pancreatic ductal epithelium, protecting against pancreatitis by promoting pancreatic ductal output to limit autodigestion and inflammation. CLDN2 up-regulation is a pathophysiological response to inflammation, and absence of CLDN2 exacerbates disease severity. Modulating pancreatic ductal CLDN2 function represents a potential therapeutic strategy for pancreatitis.
中文摘要:胰腺炎受环境和遗传因素影响。全基因组关联研究已发现X连锁CLDN2位点的多态性是慢性胰腺炎的危险因素。CLDN2编码紧密连接处的旁细胞阳离子选择性通道claudin-2(CLDN2)。然而,其在胰腺炎易感性中的作用仍不明确。我们旨在确定CLDN2在胰腺炎发生和进展中的作用。使用人胰腺组织、胰腺炎小鼠模型、胰腺导管上皮类器官和分离的小鼠胰腺导管。评估了CLDN2表达、细胞因子对其的调节及其对胰腺炎症、纤维化和导管液体转运的影响。CLDN2在人慢性胰腺炎以及雨蛙素诱导和T7D23A突变小鼠模型中均上调。干扰素-γ在类器官和小鼠胰腺中提高了CLDN2的RNA和蛋白表达水平。与野生型小鼠相比,Ifng敲除(KO)小鼠中雨蛙素诱导的CLDN2上调减少。在功能上,Cldn2 KO小鼠在短期雨蛙素处理诱导的急性胰腺炎以及雨蛙素和酒精处理诱导的慢性胰腺炎模型中均出现更严重的疾病。基于类器官的研究显示,CLDN2对钠依赖性水转运以及由腺苷3',5'-环磷酸(cAMP)驱动的、囊性纤维化跨膜传导调节因子依赖的和对4,4'-二异硫氰基-2,2'-二苯乙烯二磺酸敏感的液体分泌至关重要。最后,使用分离胰腺导管的研究显示,佛司可林刺激的液体分泌需要CLDN2。这些发现提示,旁细胞CLDN2与跨细胞转运体之间的功能性交互作用对于胰腺导管上皮的液体分泌至关重要,可通过促进胰腺导管输出以限制自身消化和炎症,从而防止胰腺炎。CLDN2上调是对炎症的病理生理反应,而CLDN2缺失会加重疾病严重程度。调节胰腺导管CLDN2功能是胰腺炎的一种潜在治疗策略。
Chronic pancreatitis is a progressive fibroinflammatory disease of the pancreas that causes recurrent or chronic abdominal pain and functional insufficiency. Chronic pancreatitis follows the conceptual model of acinar cell injury, which leads to inflammation and finally fibrosis, resulting in progressively worsening morphologic and functional changes in the pancreas. The diagnosis is generally made in the presence of pancreatic duct dilatation or calcification, or both, which represents an advanced form of the disease. The diagnosis of the early stage of the disease remains challenging due to a lack of validated biomarkers and limited access to histopathologic assessment. Thus, the current treatment strategy primarily focuses on relieving pancreatic ductal obstruction via endoscopic or surgical intervention in advanced chronic pancreatitis. Our understanding of the early pathophysiological events, particularly the mechanisms of inflammation, is limited. This has hampered progress in developing disease-modifying therapies to prevent and retard disease progression. This review focuses on mechanisms of inflammation, pathways of progression from early- to late-stage disease, and current and emerging therapies with the potential to modify the clinical trajectory of chronic pancreatitis. A patient-tailored approach to therapy that limits inflammation and preserves organ function should be developed in the future.
中文摘要:慢性胰腺炎是一种进行性纤维炎症性胰腺疾病,可引起反复或慢性腹痛及功能不全。慢性胰腺炎遵循腺泡细胞损伤、进而炎症、最终纤维化的概念模型,导致胰腺形态和功能改变逐步加重。诊断通常在存在胰管扩张和/或钙化时作出,而这代表疾病的晚期形式。由于缺乏经过验证的生物标志物且组织病理学评估的可及性有限,早期阶段诊断仍具挑战。因此,当前治疗策略主要集中于通过内镜或手术干预解除晚期慢性胰腺炎的胰管梗阻。我们对早期病理生理事件,尤其是炎症机制的理解仍然有限。这阻碍了开发可预防和延缓疾病进展的疾病修饰疗法的进展。本综述关注炎症机制、从早期向晚期疾病进展的途径,以及当前和新兴的、有可能改变慢性胰腺炎临床轨迹的疗法。未来应发展一种以患者为中心、限制炎症并保留器官功能的治疗方法。
4NAFLD/NASH/代谢肝病 (6篇)
临床研究 (3篇)
Resmetirom, a thyroid hormone receptor beta agonist, improves metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients with non-cirrhotic MASH. Risk genotypes of PNPLA3, HSD17B13, TM6SF2, MTARC1, MBOAT7, and SERPINA1 have been associated with altered susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD), MASH, fibrosis, cirrhosis, and/or hepatocellular carcinoma. We evaluated the impact of MASLD risk genotypes on baseline characteristics and the response to resmetirom vs. placebo with respect to MASH, fibrosis, MRI-proton density fat fraction (MRI-PDFF), and other biomarkers. Testing the effects of MASLD risk genotypes or combinations of high-risk alleles on liver biopsy, MRI-PDFF, and biomarker responses to resmetirom was a pre-specified analysis in 738 patients enrolled in the MAESTRO-NASH phase III trial who consented to DNA collection, were genotyped for all genes, and had liver biopsies at baseline and Week 52. At baseline, patients with high-risk genotypes of PNPLA3 or HSD17B13 had a lower frequency of metabolic risk factors, including type 2 diabetes mellitus and hypertension, than patients with low-risk genotypes. Interaction analyses and efficacy assessments indicated that resmetirom had similar positive effects on MASH resolution, fibrosis improvement on liver biopsy, MRI-PDFF response, and biomarkers at Week 52 in MAESTRO-NASH patients with high-risk genotypes of PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7, either individually or as part of a composite genetic risk score. These effects were independent of sex, Hispanic ethnicity, and metabolic risk factors. Due to the limited sample size, the study was not powered to detect small effects of risk genotypes on resmetirom efficacy. Resmetirom's effects on MASH, liver fibrosis, MRI-PDFF, and MASH biomarkers in the MAESTRO-NASH trial were not significantly impacted by the presence of common MASH risk genotypes, suggesting that resmetirom's mechanism of action may help mitigate the deleterious effects of MASH risk variants. Number: NCT03900429 IMPACT AND IMPLICATIONS: Resmetirom has recently been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). It leads to MASH resolution and improvement of fibrosis in patients with non-cirrhotic MASH. Patients with MASH have higher prevalence of certain genetic variants which can be associated with more severe disease. In this study we evaluated the relationship between the presence of select MASH risk genotypes (e.g. PNPLA3, TM6SF2, or HSD17B13) or the combined total of MASH genetic risk alleles on the response to resmetirom and placebo in 738 patients with non-cirrhotic MASH with serial liver biopsies at baseline and week 52. Within the limitation of study sample size, resmetirom's benefits on MASH resolution, fibrosis improvement and hepatic steatosis were independent of the presence of MASH genetic risk genotypes either alone or in combination.
中文摘要:Resmetirom是一种甲状腺激素受体β激动剂,可改善非肝硬化MASH患者的代谢功能障碍相关脂肪性肝炎(MASH)和肝纤维化。PNPLA3、HSD17B13、TM6SF2、MTARC1、MBOAT7和SERPINA1的风险基因型与代谢功能障碍相关脂肪性肝病(MASLD)、MASH、纤维化、肝硬化和/或肝细胞癌易感性的改变相关。我们评估了MASLD风险基因型对基线特征以及Resmetirom与安慰剂相比在MASH、纤维化、MRI质子密度脂肪分数(MRI-PDFF)和其他生物标志物方面应答的影响。在MAESTRO-NASH III期试验中入组的738例患者中,检测MASLD风险基因型或高风险等位基因组合对肝活检、MRI-PDFF和生物标志物对Resmetirom应答的影响是一项预设分析;这些患者同意采集DNA,接受了所有基因的基因分型,并在基线和第52周进行了肝活检。基线时,PNPLA3或HSD17B13高风险基因型患者中包括2型糖尿病和高血压在内的代谢危险因素出现频率低于低风险基因型患者。交互分析和疗效评估表明,在具有PNPLA3、HSD17B13、TM6SF2、MTARC1和MBOAT7高风险基因型(无论是单个基因还是作为复合遗传风险评分的一部分)的MAESTRO-NASH患者中,Resmetirom在第52周对MASH消退、肝活检纤维化改善、MRI-PDFF应答和生物标志物具有相似的阳性效应。这些效应独立于性别、西班牙裔族裔和代谢危险因素。由于样本量有限,本研究不足以检测风险基因型对Resmetirom疗效的微小影响。在MAESTRO-NASH试验中,常见MASH风险基因型的存在未显著影响Resmetirom对MASH、肝纤维化、MRI-PDFF和MASH生物标志物的效应,提示Resmetirom的作用机制可能有助于减轻MASH风险变异的有害影响。编号:NCT03900429 影响与意义:Resmetirom最近已被批准用于治疗代谢功能障碍相关脂肪性肝炎(MASH)。它可使非肝硬化MASH患者实现MASH消退和纤维化改善。MASH患者中某些遗传变异的患病率较高,这些变异可能与更严重的疾病相关。在本研究中,我们评估了选定MASH风险基因型(例如PNPLA3、TM6SF2或HSD17B13)的存在或MASH遗传风险等位基因总和与738例非肝硬化MASH患者对Resmetirom和安慰剂应答之间的关系,这些患者在基线和第52周进行了连续肝活检。在研究样本量的限制内,Resmetirom对MASH消退、纤维化改善和肝脂肪变性的益处独立于MASH遗传风险基因型的存在,无论是单独存在还是联合存在。
Cellular senescence plays an important role in hepatic inflammation and fibrosis1-3. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (-1.43 ± 1.22 versus -0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488 .
中文摘要:细胞衰老在肝脏炎症和纤维化中发挥重要作用。然而,衰老是否可作为代谢功能障碍相关脂肪性肝炎(MASH)患者的潜在治疗靶点,仍尚未得到探索。本研究报道了一项在纤维化性MASH受试者中开展的2期、双盲、随机、安慰剂对照试验结果,该试验评估达沙替尼联合槲皮素(D+Q)的间歇性衰老细胞清除治疗。31名受试者(中位年龄56岁;76%为男性;58%合并2型糖尿病)按1:1随机分配接受D+Q(达沙替尼100 mg/天联合槲皮素1,000 mg/天)或安慰剂治疗,每周连续3天给药,持续3周,并在三个7周周期中重复。主要终点为配对肝活检中纤维化改善≥1期且MASH无恶化,D+Q治疗组有47%达到,而安慰剂组为7%(P=0.02)。MASH缓解在D+Q组较安慰剂组更常见(53%对7%;P=0.02),且NAFLD活动度评分下降幅度更大(-1.43±1.22对-0.39±0.77;P=0.012)。单核RNA测序显示,D+Q组衰老和纤维化基因特征降低,促纤维化细胞群减少。尽管D+Q组不良事件更常见(82%对43%),但均为自限性。总体而言,这项原理验证试验支持未来在纤维化性MASH中开展衰老细胞清除治疗试验的必要性。ClinicalTrials.gov注册号:NCT05506488。
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a prevalent condition affecting 25-30% of the global population and is closely linked to obesity, type 2 diabetes, and other cardiometabolic risk factors. Although liver biopsy remains the gold standard for diagnosis, its invasive nature has prompted a shift toward non-invasive biomarkers for disease assessment, staging, and monitoring. Multiple non-invasive biomarkers have been studied or are currently under investigation to assess both fibrosis and steatosis among patients with MASLD. This review aims to summarize the current literature on emerging and established biomarkers for MASLD, focusing on their roles in detecting inflammation, fibrosis, metabolic dysfunction, and steatosis, including imaging-based surrogate endpoints and composite biomarker panels.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD),既往称为非酒精性脂肪性肝病(NAFLD),是一种常见疾病,影响全球人口的25-30%,并与肥胖、2型糖尿病及其他心血管代谢危险因素密切相关。尽管肝活检仍是诊断的金标准,但其有创性促使人们转向采用非侵入性生物标志物进行疾病评估、分期和监测。目前已研究或正在研究多种非侵入性生物标志物,用于评估MASLD患者的纤维化和脂肪变。本综述旨在总结关于MASLD新兴和已确立生物标志物的现有文献,重点关注其在检测炎症、纤维化、代谢功能障碍和脂肪变中的作用,包括基于影像学的替代终点和复合生物标志物组合。
基础研究 (3篇)
Metabolic dysfunction-associated steatotic liver disease (MASLD) severity is independently linked with pathogenic CD4+ T cell responses and skewed hepatic glutamine (Gln) metabolism. Whether these processes interact to drive disease progression remains unclear. Here, we identify hepatic Gln depletion as a key feature of steatohepatitis that is linked with increased hepatic CD4+ T cell inflammation and hepatocellular damage in humans. In complementary mouse models, both total hepatic and hepatic CD4+ T cell Gln levels were similarly reduced. Restoration of hepatic Gln through supplementation selectively restrained hepatic CD4+ T cell inflammatory programs and alleviated hepatocellular damage and disease severity. Mechanistically, T cell-intrinsic Gls1-mediated glutaminolysis limited O-GlcNAcylation to dampen pathogenic CD4+ T cell inflammation. Importantly, Gln treatment dampened CD4+ T cell-mediated injury in human liver organoids. Together, these findings establish hepatic CD4+ T cell-intrinsic Gln metabolism as a critical rheostat of pathogenic inflammation in MASLD and invoke metabolism-targeted strategies to restrict disease progression.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)的严重程度与致病性CD4+ T细胞反应以及肝脏谷氨酰胺(Gln)代谢的异常偏移独立相关。这些过程是否相互作用以驱动疾病进展仍不清楚。在此,我们确认肝脏Gln耗竭是脂肪性肝炎的一个关键特征,并且在人类中与肝脏CD4+ T细胞炎症增加和肝细胞损伤相关。在相应的互补小鼠模型中,肝脏总体及肝脏CD4+ T细胞内的Gln水平同样降低。通过补充恢复肝脏Gln可选择性地抑制肝脏CD4+ T细胞的炎症程序,并减轻肝细胞损伤与疾病严重程度。在机制上,T细胞内在的Gls1介导的谷氨酰胺分解限制了O-GlcNAcylation,从而抑制致病性CD4+ T细胞炎症。重要的是,Gln处理可减轻人肝类器官中CD4+ T细胞介导的损伤。总之,这些发现确立了肝脏CD4+ T细胞内在的Gln代谢是MASLD致病性炎症的关键调节器,并提示可采用靶向代谢的策略来限制疾病进展。
Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) frequently co-occur, driven by inter-organ metabolic crosstalk that current single-target therapies fail to disrupt. This review reframes NAFLD-CVD comorbidity through a materials-first lens and advances a translational design framework that couples pathophysiology with engineering principles. We synthesize three major pathological axes, including lipid overflow and impaired reverse cholesterol transport, inflammation-oxidative stress amplification driven by Kupffer cell-NLRP3 and mitochondrial ROS/MAPK signaling, as well as gut-liver-vascular dysregulation involving bile acid FXR/TGR5 pathways and microbiota-derived metabolites, and further map these mechanisms to organ-selective and stimulus-responsive therapeutic interventions. Specifically, we highlight liver-heart co-targeting via GalNAc/ASGPR and VCAM-1 ligands, HDL-mimetic and exosome platforms that restore cholesterol efflux, ROS/pH/enzyme-responsive carriers that achieve microenvironment-triggered release and mitochondria-addressed nanodevices including antioxidant nanozymes, Mito-therapeutics, and optogenetically guided CRISPR/RNA payloads that recalibrate energy/redox homeostasis. We further outline macrophage-reprogramming strategies using cytokine mRNA and miRNA modulators to resolve chronic inflammation, and propose closed-loop systems that integrate AI-guided design with synthetic biology circuits for adaptive, multi-organ control. Across platforms, we distill actionable criteria covering clinical translation, biodistribution fidelity, barrier traversal, compensation-proof multi-pathway control, and safety-by-design. This materials-anchored roadmap moves the field from single-organ symptom control to systemic metabolic reprogramming, positioning advanced materials as catalysts for durable, precision therapy in NAFLD-CVD comorbidity.
中文摘要:非酒精性脂肪性肝病(NAFLD)和心血管疾病(CVD)常同时发生,其驱动因素是当前的单一靶点治疗无法打断的器官间代谢串扰。本综述通过材料优先的视角重新审视NAFLD-CVD共病,并提出一个将病理生理学与工程学原理相结合的转化设计框架。我们综合了三条主要病理轴,包括脂质溢出和逆向胆固醇转运受损、由库普弗细胞-NLRP3以及线粒体ROS/MAPK信号驱动的炎症-氧化应激放大,以及涉及胆汁酸FXR/TGR5通路和微生物群衍生代谢物的肠-肝-血管调节异常,并进一步将这些机制映射到器官选择性和刺激响应性治疗干预。具体而言,我们强调通过GalNAc/ASGPR和VCAM-1配体实现肝-心共靶向,恢复胆固醇外排的HDL模拟和外泌体平台,实现微环境触发释放的ROS/pH/酶响应载体,以及线粒体靶向纳米装置,包括抗氧化纳米酶、Mito治疗剂和光遗传学引导的CRISPR/RNA载荷,以重新校准能量/氧化还原稳态。我们进一步概述使用细胞因子mRNA和miRNA调节剂重编程巨噬细胞的策略以消退慢性炎症,并提出将AI引导设计与合成生物学回路整合的闭环系统,用于适应性、多器官控制。在各平台中,我们提炼出涵盖临床转化、生物分布保真度、屏障穿越、抗补偿多通路控制和安全源于设计的可操作标准。这一以材料为锚点的路线图推动该领域从单器官症状控制转向系统性代谢重编程,将先进材料定位为NAFLD-CVD共病持久精准治疗的催化剂。
Non-alcoholic fatty liver disease (NAFLD) is an obesity or drug injury-induced chronic disease characterized by abnormal lipid deposition in the liver. For drug-induced non-obese NAFLD patients, timely theranostic intervention is crucial to prevent progression towards liver cancer. An intrinsically fluorescent anti-NAFLD drug with hepatic fat-targeting capability could provide an integrated theranostic solution to enable simultaneous diagnosis, treatment, and real-time efficacy monitoring in NAFLD patients. Herein, we developed a nanodrug-LIGHT (lipid droplet-guiding and hepatotropic targeting) with high affinity for intracellular lipid droplets and rapid hepatotropic accumulation following intravenous administration. LIGHT reduced lipid deposition in free fatty acids (FFAs)-induced steatosis hepatocyte model. For NAFLD mice model, LIGHT enabled real-time monitoring of the lesion site changes accompanied by restoring fatty liver to normal morphology and function. The integrated strategy of "target-image-therapy" simplifies theranostic operation and improves the efficacy in NAFLD treatment.
中文摘要:非酒精性脂肪性肝病(NAFLD)是一种由肥胖或药物损伤诱导的慢性疾病,以肝脏内脂质异常沉积为特征。对于药物诱导的非肥胖NAFLD患者,及时进行诊疗一体化干预对于防止其向肝癌进展至关重要。一种具有肝脏脂肪靶向能力且本身具有荧光的抗NAFLD药物,可提供集成的诊疗一体化解决方案,从而实现对NAFLD患者的同步诊断、治疗和实时疗效监测。在此,我们开发了一种纳米药物-LIGHT(脂滴引导和肝靶向),其对细胞内脂滴具有高亲和力,并在静脉注射后快速在肝脏富集。LIGHT减少了游离脂肪酸(FFAs)诱导的脂肪变性肝细胞模型中的脂质沉积。在NAFLD小鼠模型中,LIGHT能够实时监测病变部位变化,同时使脂肪肝恢复正常形态和功能。「靶向-成像-治疗」的整合策略简化了诊疗一体化操作,并提高了NAFLD治疗的疗效。
5炎症性肠病 (4篇)
基础研究 (4篇)
The intestinal epithelium undergoes continuous regeneration driven by intestinal stem cells (ISCs) residing within the crypt niche. Traditionally, this niche has been viewed as a stromal signaling compartment governed by gradients of Wnt, bone morphogenetic protein, and Notch activity. However, recent advances have revealed regulation via far more complex multicellular networks integrating stromal, immune, vascular, neuronal, and glial signals. In this review, we discuss emerging evidence positioning the enteric nervous system as a regulator of epithelial differentiation, regeneration, and mucosal immunity. Collectively, these findings support a revised model in which the ISC niche functions as an extended neuroglial-immune sensory unit. Understanding this integrated regulatory architecture may provide new therapeutic opportunities for inflammatory bowel disease, infection, impaired regeneration, and neuroimmune disorders of the gut.
中文摘要:肠上皮由位于隐窝微环境中的肠干细胞(ISCs)驱动,持续进行再生。传统上,该微环境被视为一个由Wnt、骨形态发生蛋白和Notch活性梯度调控的基质信号区室。然而,近期进展揭示其受到远为复杂的多细胞网络调控,该网络整合了基质、免疫、血管、神经元和胶质细胞信号。在这篇综述中,我们讨论新出现的证据,这些证据将肠神经系统定位为上皮分化、再生和黏膜免疫的调节者。总体而言,这些发现支持一个修正后的模型,即肠干细胞微环境作为一个扩展的神经胶质-免疫感觉单元发挥作用。理解这一整合的调控架构可能为炎症性肠病、感染、再生受损以及肠道神经免疫疾病提供新的治疗机会。
Bile acids (BAs), cholesterol-derived amphipathic metabolites which are traditionally regarded as digestive surfactants, are now recognized as pleiotropic signaling molecules that act through ligand-, receptor-, and tissue-specific mechanisms to maintain systemic homeostasis. They exert biological functions via nuclear receptors (FXR, PXR, VDR, CAR) and membrane receptors (TGR5, S1PR2, MRGPRX4). These receptors activate transcriptional and membrane-initiated programs, including FXR-SHP/FGF19 feedback, TGR5-cAMP-PKA signaling, S1PR2-ERK/AKT/RhoA pathways, MRGPRX4-dependent Ca2⁺ signaling, PXR/CAR/VDR-driven detoxification responses, and non-receptor-mediated membrane and mitochondrial stress pathways. This review discusses how the diversity of BA structures, hepatic synthesis, conjugation, transportation, enterohepatic circulation, and microbiota-mediated transformation generates receptor- and tissue-specific signals. Furthermore, we summarize the physiological functions of BA signaling in lipid, glucose, and energy metabolism, intestinal epithelial integrity, mucosal immunity, neuroendocrine regulation, musculoskeletal adaptation, and renal water-salt balance. Additionally, we discuss the effects of disrupted BA signaling on cholestatic and metabolic liver diseases, alcohol-associated liver disease, hepatocellular carcinoma, inflammatory bowel disease, BA diarrhea, colorectal cancer, obesity, type 2 diabetes, atherosclerosis, and biliary tract diseases. Finally, the therapeutic strategies that modulate BA signaling, including the use of FXR and TGR5 agonists, FGF19 analogues, transporter inhibitors, enzyme-targeting methods, microbiota-based treatments, and hydrophilic BA therapies, are evaluated. By categorizing BA biology according to the production of ligands, receptor activation, tissue responses, and disease mechanisms, this review highlights BA signaling as an integrated regulatory network and a tractable therapeutic axis in health and disease.
中文摘要:胆汁酸(BAs)是由胆固醇衍生的两亲性代谢物,传统上被视为消化表面活性剂,如今被认为是通过配体、受体和组织特异性机制发挥多效性信号分子作用,以维持全身稳态。它们通过核受体(FXR、PXR、VDR、CAR)和膜受体(TGR5、S1PR2、MRGPRX4)发挥生物学功能。这些受体激活转录及膜启动的程序,包括 FXR-SHP/FGF19 反馈、TGR5-cAMP-PKA 信号、S1PR2-ERK/AKT/RhoA 通路、MRGPRX4 依赖性 Ca²⁺ 信号、PXR/CAR/VDR 驱动的解毒反应以及非受体介导的膜和线粒体应激通路。本综述讨论了胆汁酸结构的多样性、肝脏合成、结合、转运、肠肝循环以及微生物群介导的转化如何产生受体和组织特异性信号。此外,我们总结了胆汁酸信号在脂质、葡萄糖和能量代谢、肠上皮完整性、黏膜免疫、神经内分泌调节、肌肉骨骼适应和肾脏水盐平衡中的生理功能。另外,我们讨论了胆汁酸信号紊乱对胆汁淤积性和代谢性肝病、酒精相关性肝病、肝细胞癌、炎症性肠病、胆汁酸性腹泻、结直肠癌、肥胖、2型糖尿病、动脉粥样硬化和胆道疾病的影响。最后,评估了调节胆汁酸信号的治疗策略,包括使用 FXR 和 TGR5 激动剂、FGF19 类似物、转运体抑制剂、靶向酶的方法、基于微生物群的治疗以及亲水性胆汁酸疗法。通过按照配体产生、受体激活、组织反应和疾病机制对胆汁酸生物学进行分类,本综述强调胆汁酸信号是一个整合的调控网络,也是健康和疾病中可干预的治疗轴。
Interleukin-17 (IL-17) family cytokines drive protective mucocutaneous immunity and, when dysregulated, a broad spectrum of inflammatory and autoimmune disease; almost all IL-17 receptor signaling converges on a single cytoplasmic adaptor, TRAF3IP2 (Act1/CIKS). This 574-amino-acid protein and U-box E3 ubiquitin ligase couples the IL-17 receptor to NF-κB and mitogen-activated protein kinase activation and also integrates non-IL-17 inputs through TRAF6, TRAF2/TRAF5, and TRAF3. Human germline variation in TRAF3IP2 offers a natural dissection of this adaptor along its signaling modules. Common coding variants that weaken TRAF6 recruitment, mainly rs33980500 (p.Asp19Asn), increase susceptibility to psoriasis and psoriatic arthritis, whereas rare biallelic variants that abolish SEFIR-mediated IL-17 receptor coupling cause chronic mucocutaneous candidiasis; an intermediate SEFIR lesion produces discoid lupus erythematosus. Additional associations span systemic lupus erythematosus, inflammatory bowel disease, cardiovascular disease, and malignancy. Interpreting these alleles has been limited by the absence of a variant catalogue anchored to a single protein reference and by a +9-residue offset between the 574- and 565-amino-acid isoforms that has propagated numbering errors across the literature. Here we assemble a reference-aligned atlas of 17 functionally or clinically annotated TRAF3IP2 variants on the 574-amino-acid sequence (NP_671733.2) and map each to the signaling interaction it perturbs. The resulting domain-to-phenotype framework, advanced as hypothesis-generating rather than deterministic, organizes variant effects along the IL-17 signaling axis, distinguishing TRAF-recruitment perturbation from receptor-coupling failure, and identifies the adaptor surfaces whose selective pharmacologic disruption could attenuate IL-17-driven inflammation in cardiovascular and oncologic disease while sparing antifungal immunity.
中文摘要:白细胞介素-17(IL-17)家族细胞因子驱动保护性黏膜皮肤免疫,当其失调时可导致广谱炎症性和自身免疫性疾病;几乎所有IL-17受体信号均汇聚于单一胞质衔接蛋白TRAF3IP2(Act1/CIKS)。这种由574个氨基酸组成的蛋白及U-box E3泛素连接酶将IL-17受体与NF-κB及丝裂原活化蛋白激酶激活偶联,还通过TRAF6、TRAF2/TRAF5和TRAF3整合非IL-17输入信号。人类TRAF3IP2胚系变异为沿其信号模块剖析该衔接蛋白提供了天然途径。削弱TRAF6募集功能的常见编码变异,主要是rs33980500(p.Asp19Asn),增加银屑病和银屑病关节炎易感性;而消除SEFIR介导的IL-17受体偶联的罕见双等位基因变异导致慢性黏膜皮肤念珠菌病;SEFIR的中间型损伤则引起盘状红斑狼疮。其他关联涵盖系统性红斑狼疮、炎症性肠病、心血管疾病和恶性肿瘤。对这些等位基因的解读一直受限,原因在于缺乏以单一蛋白参考序列为锚定的变异目录,以及574个氨基酸和565个氨基酸异构体之间存在+9个残基的偏移,这导致文献中编号错误传播。在此,我们构建了在574个氨基酸序列(NP_671733.2)上按参考序列比对排列的17个具有功能或临床注释的TRAF3IP2变异图谱,并将每个变异映射到其干扰的信号相互作用。由此产生的结构域到表型框架作为产生假设而非确定性的框架提出,沿IL-17信号轴组织变异效应,区分TRAF募集扰动与受体偶联失败,并识别衔接蛋白表面,其选择性药理学破坏可在心血管疾病和肿瘤疾病中减弱IL-17驱动的炎症,同时保留抗真菌免疫。
Autoimmune and inflammatory diseases are characterized by multifaceted pathogenesis, demanding effective therapeutic strategies. TNFSF10 is typically regarded as a pro-apoptotic ligand, yet its functions under physiological and pathological conditions remain elusive. scRNA-seq analysis of immune cells from patients with aplastic anemia (AA) was performed to identify the crucial DEGs,with TNFSF10 being highlighted as a key regulator. Tnfsf10-deficient mice were used to establish an AA mouse model, and other mouse models, such as ER stress, aGVHD, radiation-induced aging, and IBD, which facilitated the exploration of the biological function of TNFSF10. Here, we show that TNFSF10 contributes to the imbalance of immune homeostasis and immunogenic cell death (ICD) under pathological circumstances. The ICD-provoking effect and proinflammatory property of TNFSF10 is associated with the activation of the NF-κB pathway and NLRP3 inflammasome. Additionally, TNFSF10 is a crucial amplifier of endoplasmic reticulum stress by enhancing the expression of PPP1R15A, thereby contributing to NLRP3 inflammasome activation. Moreover, TNFSF10-associated ER stress is a driver of surface Calreticulin (CALR) exposure, which transmits an "eat me" signal to hyperactivated immune cells and accelerates the clearance of hematopoietic cells. We also found that AA-specific exosomes may contribute to ER stress and the expression of TNFSF10. Collectively, our study reveals the key role of TNFSF10 in autoimmune and inflammatory diseases, integrating the NF-κB, NLRP3 inflammasome, and ER stress pathways, and further accelerating the disease process.
中文摘要:自身免疫性和炎症性疾病具有多方面的发病机制,需要有效的治疗策略。TNFSF10通常被视为一种促凋亡配体,但其在生理和病理条件下的功能仍不清楚。我们对再生障碍性贫血(AA)患者的免疫细胞进行了scRNA-seq分析,以鉴定关键差异表达基因(DEGs),其中TNFSF10被凸显为关键调控因子。我们使用Tnfsf10缺陷小鼠建立AA小鼠模型,并采用其他小鼠模型,如内质网应激、aGVHD、辐射诱导衰老和IBD模型,从而促进了对TNFSF10生物学功能的探索。本研究表明,TNFSF10在病理情况下促进免疫稳态失衡和免疫原性细胞死亡(ICD)。TNFSF10诱导ICD的作用和促炎特性与NF-κB通路及NLRP3炎症小体的激活相关。此外,TNFSF10通过增强PPP1R15A表达而成为内质网应激的重要放大因子,从而促进NLRP3炎症小体激活。而且,TNFSF10相关的内质网应激是细胞表面钙网蛋白(CALR)暴露的驱动因素,后者向过度活化的免疫细胞传递「eat me」信号,并加速造血细胞的清除。我们还发现,AA特异性外泌体可能促进内质网应激和TNFSF10表达。总之,我们的研究揭示了TNFSF10在自身免疫性和炎症性疾病中的关键作用,其整合了NF-κB、NLRP3炎症小体和内质网应激通路,并进一步加速疾病进程。
6肝炎(病毒性/自免) (4篇)
临床研究 (3篇)
The impact of nucleos(t)ide analogues (NAs) therapy on the long-term outcomes in chronic HBV infection individuals outside 2025 European Association for the Study of the Liver (EASL) strongly recommended treatment indications remains uncertain. We aimed to assess the association between NAs therapy and the risks of cirrhosis and hepatocellular carcinoma (HCC) in Chinese chronic HBV infection individuals outside these criteria. We analysed data from 30 784 chronic HBV infection individuals across 12 centres in China. We categorised individuals outside 2025 EASL strongly recommended treatment criteria into four groups: (1) hepatitis B e antigen (HBeAg)-positive, high replicative (age <30, HBV DNA ≥8 log₁₀IU/mL, normal alanine aminotransferase (ALT), no/mild fibrosis, no family history of liver cancer); (2) HBeAg-positive, impending phase transition (typically age ≥30, HBV DNA ≥6 log₁₀IU/mL, normal ALT, no advanced fibrosis); (3) HBeAg-negative, low replicative (HBV DNA <3.3 log₁₀IU/mL, normal ALT, no/mild fibrosis); (4) HBeAg-negative, high replicative, low-risk (HBV DNA 3.3-4.3 log₁₀IU/mL, normal ALT, no/mild fibrosis). The primary endpoints were the incidence of cirrhosis and HCC. Up to 5 years of follow-up (117 814 person-years), we documented 635 incident cirrhosis and 164 HCC cases. In multivariable analyses, NA therapy significantly reduced risks of cirrhosis (HR 0.18, 95% CI 0.11 to 0.32) and HCC (HR 0.03, 95% CI 0.01 to 0.21) in Group 1, and cirrhosis (HR 0.50, 95% CI 0.41 to 0.61) and HCC (HR 0.25, 95% CI 0.16 to 0.41) in Group 2. No significant associations were observed in Groups 3 and 4. Findings were consistent in propensity score matching analyses. NAs therapy was associated with reduced risks of cirrhosis and HCC in HBeAg-positive individuals with high replicative or impending phase transition phenotypes, supporting the expansion of chronic HBV infection treatment criteria.
中文摘要:核(酸)类似物(NAs)治疗对2025年欧洲肝脏研究学会(EASL)强烈推荐治疗指征之外的慢性HBV感染者的长期结局影响仍不确定。我们旨在评估NAs治疗与中国慢性HBV感染者中不符合这些标准者发生肝硬化和肝细胞癌(HCC)风险之间的关联。我们分析了中国12个中心30784例慢性HBV感染者的数据。我们将不符合2025 EASL强烈推荐治疗标准者分为四组:(1)HBeAg阳性、高复制期(年龄<30岁,HBV DNA ≥8 log₁₀IU/mL,丙氨酸氨基转移酶(ALT)正常,无/轻度纤维化,无肝癌家族史);(2)HBeAg阳性、即将发生阶段转换(通常年龄≥30岁,HBV DNA ≥6 log₁₀IU/mL,ALT正常,无晚期纤维化);(3)HBeAg阴性、低复制期(HBV DNA <3.3 log₁₀IU/mL,ALT正常,无/轻度纤维化);(4)HBeAg阴性、高复制、低风险(HBV DNA 3.3-4.3 log₁₀IU/mL,ALT正常,无/轻度纤维化)。主要终点为肝硬化和HCC的发生率。在长达5年随访(117814人年)期间,我们记录了635例新发肝硬化和164例HCC病例。在多变量分析中,NA治疗显著降低了第1组肝硬化和HCC风险:肝硬化风险比(HR)0.18,95%置信区间(CI)0.11至0.32;HCC HR 0.03,95% CI 0.01至0.21。在第2组,NA治疗显著降低了肝硬化风险(HR 0.50,95% CI 0.41至0.61)和HCC风险(HR 0.25,95% CI 0.16至0.41)。第3组和第4组未观察到显著关联。倾向性评分匹配分析中结果一致。NAs治疗与HBeAg阳性且具有高复制或即将发生阶段转换表型者的肝硬化和HCC风险降低相关,支持扩大慢性HBV感染治疗标准。
Without a vaccine, HCV (re)infections continue to afflict individuals at high risk, for example, men who have sex with men (MSM). To guide vaccine development, we assessed whether natural protection against observed HCV reinfection among MSM was associated with a distinct humoral immune profile. From a prospective cohort of HIV-positive MSM with acute HCV infection (MOSAIC, Dutch MSM Observational Study of Acute Infection with hepatitis C), we selected 13 cases who became HCV-reinfected (R) and 18 controls who remained free of observed reinfections (non-reinfected, NR) in 0.5-9.5 years after primary infection clearance, matched for calendar year of primary infection. At time point T1 (29 days before to 78 days after primary clearance) and T2 (3-6 months before R subjects' first reinfection), we evaluated serum antibody responses against HCV's E1E2 envelope glycoprotein. Based solely on E1E2-binding antibody levels and Fc-gamma receptor (FcγR)/C1q engagement at T1, we divided participants into subgroups using latent profile analysis. HCV-neutralising responses were observed mainly at T1 (9/18 NR and 3/13 R participants). The NR group could be distinguished from the R group at T1 by higher levels of E1E2-binding antibodies that bound FcγRs/C1q. Among four identified latent profiles, HCV reinfection prevalence was lowest in the profile defined by moderate to high levels of E1E2-binding antibodies (IgM/IgG/IgG1/IgG3) and FcγR/C1q engagement. This profile exhibited a relatively broad, potent HCV-neutralising capacity and the broadest epitope specificity. We propose broad, potent serum Fc-mediated effector functions and neutralisation and a broad anti-E1E2 antibody epitope specificity as ingredients of HCV-protective immunity towards which vaccination approaches should aim.
中文摘要:在没有疫苗的情况下,HCV(再)感染仍持续影响高风险人群,例如男男性行为者(MSM)。为指导疫苗研发,我们评估了MSM中针对观察到的HCV再感染的自然保护是否与一种独特的体液免疫特征相关。来自一个HIV阳性MSM急性HCV感染前瞻性队列(MOSAIC,荷兰MSM急性丙型肝炎病毒感染观察研究),我们选择了13例发生HCV再感染者(R)和18例在初次感染清除后0.5-9.5年内未观察到再感染的对照者(未再感染,NR),并按初次感染日历年进行匹配。在T1时间点(初次清除前29天至清除后78天)和T2时间点(R受试者首次再感染前3-6个月),我们评估了针对HCV E1E2包膜糖蛋白的血清抗体反应。仅基于T1时E1E2结合抗体水平以及Fcγ受体(FcγR)/C1q结合,我们使用潜在剖面分析将参与者分为亚组。HCV中和反应主要在T1观察到(18例NR中9例和13例R中3例)。在T1时,NR组可通过更高水平的E1E2结合抗体且结合FcγRs/C1q与R组区分。在确定的四种潜在特征中,HCV再感染比例最低的是由中高水平E1E2结合抗体(IgM/IgG/IgG1/IgG3)和FcγR/C1q结合所定义的特征。该特征表现出相对广泛、强效的HCV中和能力以及最广泛的表位特异性。我们提出,广泛的、强效的血清Fc介导效应功能和中和作用,以及广泛的抗E1E2抗体表位特异性,是HCV保护性免疫的组成部分,疫苗策略应以此为目标。
Universal administration of hepatitis B (HepB) vaccine at birth is a cornerstone for hepatitis B virus (HBV) elimination efforts in the US. In 2025, the Advisory Committee on Immunization Practices (ACIP) recommended delaying HepB vaccine initiation among infants born to birth parents who tested negative for hepatitis B surface antigen (HBsAg). To evaluate the health and economic impact of delaying HepB vaccination among US infants. A Markov model of HBV infections was acquired among a cohort infants, born in 2025, up to age 18 years. The model incorporated HBsAg prevalence among birthing parents, HBsAg testing during pregnancy or delivery, vertical or perinatal and household or community HBV transmission among children, and sequalae from chronic infection. This study was conducted in the US. Eight scenarios in which the first HepB dose was delayed at intervals between 2 months and 12 years, applied either only to infants born to birth parents who tested negative for HBsAg or to parents who either tested negative for HBsAg or had unknown HBsAg status. All delayed vaccination scenarios were compared with administering first HepB dose at birth. Scenarios were modeled with perfect and imperfect adherence to recommendations. Outcomes included acute and chronic HBV infections acquired until age 18 years, additional associated lifetime HBV-related morbidity and mortality, and health care costs (2025 US dollars). The health and economic outcomes of 3 628 934 infants were modeled in this analysis. All delayed vaccination scenarios resulted in more infections, worse health outcomes, and higher costs than administering first HepB dose at birth. Under perfect adherence, delaying HepB vaccination by 2 months for infants of parents negative for HBsAg led to an additional 90 acute infections (range, 16-107), 76 chronic infections (range, 14-97), 29 HBV-related deaths (range, 6-53), with $16.4 million in added costs for infants born during 1 year. Delaying to 12 years resulted in an additional 190 acute infections (range, 61-233), 50 deaths (range, 15-83), and nearly $30 million in added costs. Delaying HepB vaccination among infants of parents with unknown HBsAg status or imperfect adherence to the vaccination schedule amplified all negative outcomes. Results of this economic evaluation quantified the potential impact of changing ACIP recommendations. Even brief delays in HepB vaccine initiation were associated with a substantial increase in HBV infections, adverse health outcomes, and health care costs.
中文摘要:在美国,出生时普遍接种乙型肝炎(HepB)疫苗是消除乙型肝炎病毒(HBV)工作的基石。2025年,免疫实践咨询委员会(ACIP)建议对HBsAg检测阴性的分娩父母所生婴儿延迟启动HepB疫苗接种。为评估在美国婴儿中延迟HepB疫苗接种的健康和经济影响,构建了一个2025年出生婴儿队列至18岁的HBV感染马尔可夫模型。模型纳入分娩父母中的HBsAg流行率、妊娠期或分娩时的HBsAg检测、儿童中的垂直或围产期及家庭或社区HBV传播,以及慢性感染后的后遗症。本研究在美国开展。设置了8种情景,将首剂HepB疫苗延迟2个月至12年不等,或仅适用于HBsAg检测阴性的分娩父母所生婴儿,或适用于HBsAg检测阴性或HBsAg状态未知的父母。所有延迟接种情景均与出生时接种首剂HepB疫苗进行比较。情景按完全依从和不完全依从建议进行建模。结局包括至18岁获得的急性和慢性HBV感染、额外相关的终生HBV相关发病和死亡,以及医疗费用(2025年美元)。本分析对3 628 934名婴儿的健康和经济结局进行了建模。与出生时接种首剂HepB疫苗相比,所有延迟接种情景均导致更多感染、更差的健康结局和更高的费用。在完全依从下,对HBsAg阴性父母的婴儿将HepB疫苗接种延迟2个月,导致额外90例急性感染(范围16-107)、76例慢性感染(范围14-97)、29例HBV相关死亡(范围6-53),并在一年的出生婴儿中增加1640万美元费用。延迟至12年导致额外190例急性感染(范围61-233)、50例死亡(范围15-83)和近3000万美元的额外费用。对HBsAg状态未知父母的婴儿延迟接种HepB疫苗,或对接种程序依从不完全,会放大所有负面结局。该经济学评价结果量化了改变ACIP建议的潜在影响。即使短暂延迟启动HepB疫苗,也与HBV感染、不良健康结局和医疗费用的显著增加相关。
基础研究 (1篇)
CD8+ T cell dysfunction is a major obstacle to hepatitis B virus (HBV) clearance and antitumor immunity. Here, using a humanized mouse model, we identify a T cell receptor targeting a clinically relevant HBV epitope and reveal ANKRD11 as a key epigenetic regulator of CD8+ T cell dysfunction in chronic infection and tumors. Ankrd11 knockout in CD8+ T cells enhances HBV-specific T cell proliferation and effector differentiation, especially under immunosuppressive conditions, via AP-1 family gene upregulation. Loss of Ankrd11 both drives the conversion of progenitor exhausted T cells into terminally exhausted T cells, and reprograms PD-1-TOX- tolerant cells into functional effectors, improving antiviral and antitumor responses. Ankrd11-deficient T cells show increased granzyme and superior effector function, enhancing viral control and tumor regression. These findings position ANKRD11 as a promising immunotherapy target for chronic HBV infection and cancer.
中文摘要:CD8+ T细胞功能障碍是乙型肝炎病毒(HBV)清除和抗肿瘤免疫的主要障碍。在此,我们利用人源化小鼠模型,鉴定了一种靶向临床相关HBV表位的T细胞受体,并揭示ANKRD11是慢性感染和肿瘤中CD8+ T细胞功能障碍的关键表观遗传调控因子。在CD8+ T细胞中敲除Ankrd11可通过上调AP-1家族基因,增强HBV特异性T细胞增殖和效应分化,尤其是在免疫抑制条件下。Ankrd11缺失既驱动祖细胞耗竭T细胞向终末耗竭T细胞转化,又将PD-1-TOX-耐受细胞重编程为功能性效应细胞,从而改善抗病毒和抗肿瘤反应。Ankrd11缺陷T细胞表现出颗粒酶增加和更优的效应功能,增强病毒控制和肿瘤消退。这些发现将ANKRD11定位为慢性HBV感染和癌症的有前景的免疫治疗靶点。
7病毒性肝炎 (3篇)
临床研究 (2篇)
The opioid epidemic has led to an infectious diseases syndemic, with injection drug use responsible for driving rising rates of HIV, viral hepatitis, and serious bacterial and fungal infections. Opioid use continues to cause devastating mortality, with over 80,000 opioid-involved overdose deaths in the USA in 2022. Despite the proven effectiveness of opioid agonist therapy, specifically methadone and buprenorphine, treatment coverage remains inadequate, with profound gaps in opioid use disorder (OUD) continuum of care. Injection-related infections, particularly skin and soft tissue infections, bacteremia, osteomyelitis, and infective endocarditis, have increased substantially since the early 2000s and carry a high risk of morbidity and mortality. Risk is further compounded by criminalization, stigma, incarceration, and comorbid psychiatric conditions. Emerging concerns such as xylazine-associated necrotic wounds illustrate the dynamic intersection of substance use and infectious disease. While direct-acting antivirals have made hepatitis C curable, barriers to treatment persist, and uptake of HIV prevention strategies, including pre-exposure prophylaxis, remains low among people who inject drugs. Integration of addiction treatment into infectious disease and hospital care improves outcomes, yet systemic and policy barriers limit access. Innovative models such as syringe service programs, mobile units, and inpatient addiction consult services demonstrate the feasibility of integrated, patient-centered care. Evidence gaps remain regarding optimal antibiotic strategies for serious infections in people with OUD, and research and policy must address exclusionary practices, stigma, and fragmented systems of care. A synergistic approach integrating OUD treatment, infectious disease management, risk reduction, and trauma-informed care is essential to reduce preventable deaths and improve long-term health outcomes.
中文摘要:阿片类药物流行已导致传染病协同流行,注射吸毒是推动HIV、病毒性肝炎以及严重细菌和真菌感染发生率上升的原因。阿片类药物使用仍造成毁灭性死亡,2022年美国有超过8万例涉及阿片类药物的过量死亡。尽管阿片受体激动剂治疗,尤其是美沙酮和丁丙诺啡,已被证实有效,但治疗覆盖仍不足,阿片使用障碍(OUD)连续照护存在巨大缺口。注射相关感染,尤其是皮肤软组织感染、菌血症、骨髓炎和感染性心内膜炎,自2000年代初以来大幅增加,并具有高发病和死亡风险。犯罪化、污名、监禁以及共病精神疾病进一步加剧了风险。赛拉嗪相关坏死性伤口等新出现的问题说明了物质使用与传染病之间动态交织的关系。尽管直接抗病毒药物已使丙型肝炎可治愈,但治疗障碍依然存在,且注射吸毒者对HIV预防策略(包括暴露前预防)的接受度仍然较低。将成瘾治疗整合到传染病和医院照护中可改善结局,但系统性和政策障碍限制了可及性。针具服务项目、移动单元和住院成瘾会诊服务等创新模式证明了整合式、以患者为中心的照护的可行性。对于OUD患者严重感染的最佳抗生素策略仍存在证据缺口,研究和政策必须应对排斥性做法、污名和碎片化的照护系统。整合OUD治疗、传染病管理、降低风险和创伤知情照护的协同方法对于减少可预防死亡和改善长期健康结局至关重要。
Serologic immunity to hepatitis A virus (HAV) and hepatitis B virus (HBV) protects against acute infection and severe outcomes among high-risk groups; however, contemporary data on population-level immunity remain limited, especially in high-risk populations. To estimate the prevalence and factors associated with serologic immunity in the overall population and across high-risk subgroups, including those with chronic liver disease (CLD), chronic kidney disease, diabetes, and immunosuppression and pregnant people. This cross-sectional study used data from the National Health and Nutrition Examination Survey from January 2017 to August 2023 and included adults aged 20 years or older with available HAV and HBV serologic test results. Data were analyzed from January 3 to May 10, 2026. The primary outcomes were the prevalence of serologic immunity to HAV, defined by hepatitis A antibody positivity, and HBV, defined by hepatitis B surface antibody positivity, with vaccine-derived immunity specifically identified by surface antibody positivity in the absence of hepatitis B core antibodies. Data were weighted to generate nationally representative estimates of the US adult population. Multivariable survey-weighted logistic regression models were used to identify independent factors associated with viral hepatitis immunity. Among 13 514 individuals, representing an estimated 226.1 million US adults (mean [SE] age, 48.65 [0.40] years; 51.76% female), 39.5% (95% CI, 37.7%-41.3%) demonstrated serologic immunity to hepatitis A, corresponding to approximately 89.4 million individuals. For HBV, 27.1% (95% CI, 25.8%-28.4%) demonstrated serologic immunity, corresponding to approximately 61.3 million individuals, while vaccine-derived immunity was present in 25.2% (95% CI, 23.9%-26.5%). In adjusted models, HAV immunity was associated with younger age (eg, 20-29 vs ≥65 years: adjusted odds ratio [AOR], 0.51; 95% CI, 0.44-0.60); lower educational attainment (eg,
中文摘要:对甲型肝炎病毒(HAV)和乙型肝炎病毒(HBV)的血清学免疫可保护高危人群免受急性感染和严重结局影响;然而,关于人群水平免疫的当代数据仍有限,尤其是在高危人群中。旨在估计总体人群及高危亚组(包括慢性肝病(CLD)、慢性肾病、糖尿病、免疫抑制者和孕妇)中血清学免疫的患病率及相关因素。本横断面研究使用2017年1月至2023年8月美国国家健康与营养调查数据,纳入20岁及以上且具有可用HAV和HBV血清学检测结果的成人。数据分析时间为2026年1月3日至5月10日。主要结局为HAV血清学免疫患病率,定义为甲型肝炎抗体阳性;以及HBV血清学免疫患病率,定义为乙型肝炎表面抗体阳性,其中疫苗诱导免疫特指在无乙型肝炎核心抗体情况下的表面抗体阳性。数据经加权以生成美国成人全国代表性估计。使用多变量调查加权logistic回归模型识别与病毒性肝炎免疫独立相关的因素。在13 514名个体中,代表约2.261亿美国成人(平均[SE]年龄48.65[0.40]岁;51.76%女性),39.5%(95% CI,37.7%-41.3%)显示对甲型肝炎的血清学免疫,约对应8940万人。对于HBV,27.1%(95% CI,25.8%-28.4%)显示血清学免疫,约对应6130万人,而疫苗诱导免疫存在于25.2%(95% CI,23.9%-26.5%)。在调整模型中,HAV免疫与较年轻年龄(例如20-29岁 vs ≥65岁:调整比值比[AOR],0.51;95% CI,0.44-0.60)、较低教育程度(例如<9年级 vs 大学毕业生或以上:AOR,0.32;95% CI,0.24-0.42)、非西班牙裔黑人(AOR,1.67;95% CI,1.34-2.09)、墨西哥裔美国人(AOR,4.22;95% CI,3.42-5.21)、其他西班牙裔(AOR,2.01;95% CI,1.60-2.54)、非西班牙裔亚裔(AOR,3.03;95% CI,2.45-3.76)以及多种族或其他(AOR,1.36;95% CI,1.04-1.79)种族和族裔;在美国以外出生(AOR,4.54;95% CI,3.74-5.52);以及肝病知晓(OR,1.65;95% CI,1.29-2.09)相关。肥胖与HAV免疫几率较低相关(AOR,0.83;95% CI,0.72-0.96)。疫苗诱导的HBV免疫与较年轻年龄(例如20-29岁 vs ≥65岁:AOR,0.18;95% CI,0.15-0.23)、女性(AOR,1.36;95% CI,1.18-1.56)、非西班牙裔亚裔(AOR,1.47;95% CI,1.17-1.86)和非西班牙裔黑人(AOR,1.15;95% CI,1.00-1.32)种族和族裔,以及较高教育程度(例如<9年级 vs 大学毕业生或以上:AOR,3.29;95% CI,2.35-4.61)相关。在高危亚组中,HAV免疫范围为26.7%(95% CI,18.9%-34.4%),见于代谢功能障碍相关酒精性肝病,至63.7%(95% CI,50.0%-77.4%),见于慢性HBV感染;而HBV疫苗诱导免疫范围为14.0%(95% CI,11.3%-16.6%),见于慢性肾病,至38.6%(95% CI,28.0%-49.1%),见于妊娠。本横断面研究发现,人群水平HAV和HBV血清学免疫不理想,且在高危临床亚组中仍存在大量易感者。这些发现突显病毒性肝炎防护方面持续存在的差距,并支持针对HAV和HBV采取有针对性的系统性疫苗接种策略,尤其是在高危人群中。
基础研究 (1篇)
Our goal is to develop RNA-guided engineering of the chloroplast genome using the CRISPR/Cas9 system. We designed chloroplast minigenes to obtain properly sized single guide RNAs (sgRNAs) in tobacco chloroplasts. The sgRNA 5' end is defined by transcription from an rRNA operon promoter, and its 3' end by processing a downstream tRNA (trnG) or a hepatitis delta virus (HDV) ribozyme. Cas9 is expressed from a nuclear gene and is targeted to chloroplasts by fusion to a transit peptide. Cas9 incorporated the sgRNA and introduced double-strand breaks in the plastid DNA (ptDNA). We report here that the double-strand DNA break in the ndhA and rpoC1 genes was repaired by microhomology-mediated end joining (MMEJ), resulting in deletions in the ptDNA. We further showed that nuclear-expressed sgRNA can be delivered into chloroplasts by fusion with a viroid RNA, as one possible approach for RNA-guided engineering of the ptDNA without direct chloroplast genome transformation. These results are the first step of RNA-guided editing of the chloroplast genome in any crop.
中文摘要:我们的目标是利用CRISPR/Cas9系统开发叶绿体基因组的RNA引导工程。我们设计了叶绿体微型基因,以在烟草叶绿体中获取长度合适的单向导RNA(sgRNA)。sgRNA的5'端由rRNA操纵子启动子的转录决定,其3'端则通过加工下游的tRNA(trnG)或丁型肝炎病毒(HDV)核酶形成。Cas9由核基因表达,并通过与转运肽融合被靶向至叶绿体。Cas9结合sgRNA并在质体DNA(ptDNA)中引入双链断裂。我们在此报道,ndhA和rpoC1基因中的双链DNA断裂通过微同源介导的末端连接(MMEJ)修复,导致ptDNA发生缺失。我们进一步表明,核表达的sgRNA可通过与类病毒RNA融合被递送至叶绿体,作为无需直接转化叶绿体基因组即可进行ptDNA RNA引导工程的一种可能方法。这些结果是任何作物中叶绿体基因组RNA引导编辑的第一步。
8GERD/食管疾病 (1篇)
临床研究 (1篇)
Surveillance recommendations for Barrett esophagus (BE) are based on BE length, since the risk of progression to dysplasia or esophageal adenocarcinoma (EAC) has been shown to increase with greater BE length. The 2023 European Society for Gastrointestinal Endoscopy (ESGE) Guideline on BE advises referral to Barrett expert centers (BECs) for surveillance of ultra-long ( ≥ 10 cm) BE. This study evaluated the outcomes of expert care for patients with ultra-long BE in the Netherlands. This retrospective, nationwide cohort study including patients referred with ultra-long nondysplastic BE (NDBE) to Dutch BECs. Outcome parameters were number of cases upgraded to dysplasia/esophageal adenocarcinoma (EAC) at expert endoscopic reassessment, and number of cases with progression to high-grade dysplasia (HGD)/EAC during surveillance after a confirmed diagnosis of NDBE at expert endoscopic reassessment. 168 patients were referred with ultra-long NDBE, namely with Barrett length (median and interquartile range [IQR]), circumference (C) 11 cm (9-12), maximum (M) 12 cm (10-14). Upon expert endoscopic reassessment, 28 /168 (17 %) patients were diagnosed with dysplasia/EAC, among whom 5 /168 (3 %) had HGD/EAC in a visible lesion. In 11 patients no Seattle protocol biopsies were obtained, thus 129 patients had an NDBE diagnosis based on Seattle protocol biopsies. Of these, 95 /129 (74 %) had > 1 surveillance endoscopy at the BEC. During surveillance 20 patients progressed to LGD (n = 11, 12 %), HGD (n = 4, 4 %) or EAC (n = 5, 5 %); all progressors underwent endoscopic therapy. Expert care with dedicated BE endoscopy programs and experienced endoscopists may be beneficial for patients with ultra-long BE.
中文摘要:Barrett食管(BE)的监测建议基于BE长度,因为已显示随着BE长度增加,进展为不典型增生或食管腺癌(EAC)的风险增加。2023年欧洲胃肠道内镜学会(ESGE)关于BE的指南建议将超长(≥10 cm)BE转诊至Barrett专家中心(BEC)进行监测。本研究评估了荷兰超长BE患者接受专家诊疗的结局。这项回顾性全国性队列研究纳入转诊至荷兰BEC的超长非不典型增生性BE(NDBE)患者。结局参数为在专家内镜重新评估时升级为不典型增生/食管腺癌(EAC)的病例数,以及在专家内镜重新评估确诊NDBE后监测期间进展为高级别不典型增生(HGD)/EAC的病例数。168例患者因超长NDBE转诊,即Barrett长度(中位数和四分位距[IQR]),周长(C)11 cm(9-12),最大长度(M)12 cm(10-14)。在专家内镜重新评估时,28/168(17%)患者被诊断为不典型增生/EAC,其中5/168(3%)在可见病变中有HGD/EAC。11例患者未获得Seattle方案活检,因此129例患者基于Seattle方案活检获得NDBE诊断。其中,95/129(74%)在BEC进行了>1次监测内镜。在监测期间,20例患者进展为LGD(n=11,12%)、HGD(n=4,4%)或EAC(n=5,5%);所有进展者均接受了内镜治疗。具有专门BE内镜项目和经验丰富内镜医师的专家诊疗可能对超长BE患者有益。
9肝硬化/门脉高压 (1篇)
基础研究 (1篇)
Hypoxia following mucosal congestion in clinical practice causes a wide range of gastrointestinal symptoms and induces profound structural and functional perturbations in mitochondria-associated ER membranes (MAMs), which are subcellular compartments whose integrity and stability are regulated by FUN14 domain-containing protein 1 (FUNDC1). To investigate the effect of hypoxia-induced MAMs formation on gastric mucosal lesions in patients with severe hepatic disorders. Liver cirrhosis (LC) and hepatic failure (HF) were selected as representative severe hepatic diseases, and gastric mucosal tissues were collected. We applied the gastrointestinal symptom rating scale (GSRS) and endoscopic images to evaluate the possible relationship between gastrointestinal symptoms and mucosal lesions. Portal hypertension (PHT)-induced mouse models and hypoxia-induced cell models were also established. The roles of FUNDC1, hypoxia-induced MAMs formation and mitochondrial oxidative stress in mucosal epithelial injury were analyzed. Patients with LC or HF frequently experienced gastrointestinal symptoms, which were correlated with the progression of gastric mucosal lesions. Hypoxia induced the upregulated expression of HIF-1α in gastric mucosal tissues, which was directly associated with the FUNDC1 promoter region, thereby increasing FUNDC1 gene transcription. Moreover, METTL3-mediated m6A methylation of FUNDC1 established a posttranscriptional regulatory layer to collectively drive upregulation of FUNDC1 expression. In addition, the increased level of FUNDC1 facilitated the formation of MAMs, drove a metabolic shift toward increased glycolysis, and elicited mitochondrial reactive oxygen species (mtROS) production. Ultimately, this increase in mtROS generation promoted NINJ1 oligomerization/activation to exacerbate gastric epithelial cell death and mucosal injury. Under hypoxic conditions, FUNDC1-regulated MAMs formation and mitochondrial oxidative stress play pivotal roles in the development of gastric mucosal lesions.
中文摘要:临床实践中黏膜充血后的缺氧会引起多种胃肠道症状,并诱导线粒体相关内质网膜(MAMs)发生显著的结构和功能扰动,而MAMs是受FUN14结构域蛋白1(FUNDC1)调控其完整性和稳定性的亚细胞结构。为探讨缺氧诱导的MAMs形成对严重肝病患者胃黏膜病变的影响,选择肝硬化(LC)和肝衰竭(HF)作为代表性严重肝病,并收集胃黏膜组织。我们应用胃肠道症状评定量表(GSRS)和内镜图像评估胃肠道症状与黏膜病变之间可能的关系。同时建立门脉高压(PHT)诱导的小鼠模型和缺氧诱导的细胞模型。分析FUNDC1、缺氧诱导的MAMs形成及线粒体氧化应激在黏膜上皮损伤中的作用。LC或HF患者常出现胃肠道症状,且这些症状与胃黏膜病变进展相关。缺氧诱导胃黏膜组织中HIF-1α表达上调,其直接与FUNDC1启动子区域相关,从而增加FUNDC1基因转录。此外,METTL3介导的FUNDC1 m6A甲基化建立了转录后调控层,共同驱动FUNDC1表达上调。另外,FUNDC1水平升高促进MAMs形成,驱动代谢向糖酵解增强转变,并引发线粒体活性氧(mtROS)产生。最终,mtROS生成增加促进NINJ1寡聚化/激活,从而加剧胃上皮细胞死亡和黏膜损伤。在缺氧条件下,FUNDC1调控的MAMs形成和线粒体氧化应激在胃黏膜病变发生发展中起关键作用。
10胆管炎/PSC (1篇)
基础研究 (1篇)
Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are inflammatory bile duct disorders affecting mostly young adults that often lead to liver cirrhosis and cancer. Especially for PSC, pathogenic mechanisms remain unclear and treatment options are lacking. To better understand biliary disease processes in bile duct inflammation, we analyzed livers of NOD.c3c4 mice by spatial and single-cell (scRNA-seq) transcriptomics, identifying key cell types, interactions and potential changes over time that were validated in human liver explants. Livers of 10, 20 and 40-week-old male NOD.c3c4 mice were used for spatial transcriptomics and scRNA-seq. Differentially-expressed genes at different time points were analyzed using the CellphoneDB database with a focus on T cell-related interactions. CD226-NECTIN2 interaction was validated using co-culture experiments and antibody treatment in NOD.c3c4 mice. CD226-NECTIN2 in PSC, PBC and alcohol-related liver disease (ALD) explants was analyzed by spatial transcriptomics and immunofluorescence. Spatial transcriptomics consistently distinguished inflamed and non-inflamed liver areas in NOD.c3c4 mice at different ages. When combined with scRNA-seq enriched for immune cells and cholangiocytes, key inflammatory cell types were localized to biliary structures. Using differentially-expressed genes and a curated overview of biologically-validated interactions (CellphoneDB), the CD226-NECTIN2 T cell-cholangiocyte interaction was discovered. Knock-down of Nectin2 in vitro and anti-CD226 blocking in NOD.c3c4 mice specifically reduced T cell activation and diseased human liver showed consistent CD226-NECTIN2 co-localization at inflamed bile ducts. By combining spatial transcriptomics and scRNA-seq in NOD.c3c4 mice, we generated a pipeline for in-depth identification of potential disease relevant genes and interaction partners. The T cell-cholangiocyte interaction CD226-NECTIN2 was identified, functionally validated and detected in human disease highlighting this interaction as a possible future treatment target. PSC is an intractable immune-mediated cholestatic liver disease that mainly affects young people and has a significant impact on families and the healthcare system due to treatment costs and sick leave. Our study aimed to find new ways of understanding PSC and highlight potential treatment targets by first identifying disease-relevant cell interactions in a mouse model, followed by confirmation in human PSC livers.
中文摘要:原发性硬化性胆管炎(PSC)和原发性胆汁性胆管炎(PBC)是炎症性胆管疾病,主要影响年轻成人,常导致肝硬化和癌症。尤其对于PSC,其致病机制仍不清楚,且缺乏治疗选择。为了更好地理解胆管炎症中的胆道疾病过程,我们通过空间转录组和单细胞(scRNA-seq)转录组学分析了NOD.c3c4小鼠的肝脏,鉴定了关键细胞类型、相互作用以及随时间变化的潜在改变,并在人肝外植体中进行了验证。使用10、20和40周龄雄性NOD.c3c4小鼠的肝脏进行空间转录组学和scRNA-seq。使用CellphoneDB数据库分析不同时间点的差异表达基因,重点关注T细胞相关相互作用。通过共培养实验和NOD.c3c4小鼠中的抗体治疗验证了CD226-NECTIN2相互作用。通过空间转录组学和免疫荧光分析了PSC、PBC和酒精相关性肝病(ALD)外植体中的CD226-NECTIN2。空间转录组学一致地区分了不同年龄NOD.c3c4小鼠的炎症和非炎症肝区。当与富集免疫细胞和胆管细胞的scRNA-seq结合时,关键的炎症细胞类型被定位到胆道结构。利用差异表达基因和经过整理的生物学验证相互作用概述(CellphoneDB),发现了CD226-NECTIN2 T细胞-胆管细胞相互作用。体外敲低Nectin2以及在NOD.c3c4小鼠中阻断抗CD226,特异性降低了T细胞活化,患病的人肝脏在炎症胆管处显示出一致的CD226-NECTIN2共定位。通过在NOD.c3c4小鼠中结合空间转录组学和scRNA-seq,我们建立了一个流程,用于深入识别潜在的疾病相关基因和相互作用伙伴。T细胞-胆管细胞相互作用CD226-NECTIN2被识别、功能验证并在人类疾病中检测到,突显了该相互作用作为未来可能的治疗靶点。PSC是一种难治性免疫介导的胆汁淤积性肝病,主要影响年轻人,由于治疗费用和病假,对家庭和医疗系统产生重大影响。我们的研究旨在通过首先在小鼠模型中识别疾病相关细胞相互作用,随后在人类PSC肝脏中确认,从而找到理解PSC的新方法并突出潜在治疗靶点。
11结直肠癌 (1篇)
临床研究 (1篇)
Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide and is increasingly characterized by two converging realities: a substantial global burden and a rising incidence of early-onset CRC. This review synthesizes current advances in CRC epidemiology, risk factors, signaling biology, clinical presentation, screening, diagnosis, and management across the care continuum. We frame CRC as a systems-level disease in which genomic instability, epigenetic dysregulation, metabolic remodeling, tumor microenvironmental evolution, and gut microbiota interactions converge on interconnected pathways, including Wnt/β-catenin, MAPK, PI3K/AKT/mTOR, TGF-β, and immune-regulatory networks. We distinguish established standards of care from recent practice-changing developments and investigational strategies. Within this framework, we discuss blood-based screening, AI-assisted endoscopy, ctDNA-informed residual disease assessment, biomarker-defined molecular workup, immunotherapy strategies for dMMR disease, and targeted approaches for KRAS G12C-mutated, BRAF V600E-mutated, and HER2-positive metastatic CRC. Despite substantial progress, major challenges remain, including limited immunotherapy benefit in microsatellite-stable CRC, unequal access to high-quality screening and molecular testing, and uncertainty regarding implementation of newer biomarkers across diverse populations. An integrated framework linking population risk, tumor ecology, evidence-based biomarker use, and equitable precision care is essential for the next phase of CRC prevention and management.
中文摘要:结直肠癌(CRC)仍然是全球癌症发病和死亡的主要原因,并且日益呈现出两个趋同的现实:沉重的全球疾病负担和早发性CRC发病率的上升。本综述综合了CRC在流行病学、危险因素、信号生物学、临床表现、筛查、诊断和管理全程中的当前进展。我们将CRC视为一种系统级疾病,其中基因组不稳定性、表观遗传失调、代谢重塑、肿瘤微环境演化和肠道微生物群相互作用汇聚于相互关联的通路,包括Wnt/β-catenin、MAPK、PI3K/AKT/mTOR、TGF-β和免疫调节网络。我们区分了已确立的诊疗标准与近期改变实践的发展和处于研究阶段的策略。在此框架内,我们讨论了基于血液的筛查、人工智能辅助内镜、基于ctDNA的残留病灶评估、以生物标志物定义的分子检测、dMMR疾病的免疫治疗策略,以及针对KRAS G12C突变、BRAF V600E突变和HER2阳性转移性CRC的靶向治疗。尽管取得了实质性进展,但重大挑战仍然存在,包括免疫治疗在微卫星稳定CRC中获益有限、高质量筛查和分子检测的可及性不平等,以及新型生物标志物在不同人群中实施的不确定性。将人群风险、肿瘤生态、循证生物标志物使用和公平精准医疗联系起来的整合框架,对于CRC预防和管理的下一阶段至关重要。
12肝细胞癌 (1篇)
临床研究 (1篇)
Sex is a well-recognized factor associated with hepatocellular carcinoma (HCC) incidence, but its association with mortality is unclear. To assess the association between sex and the risk of overall, liver-related, and non-liver-related mortality among patients with HCC. This retrospective cohort study was conducted among patients with HCC in 17 centers from 5 countries and regions (2000-2023). Male and female patients with HCC who had balanced baseline characteristics via inverse probability of treatment weighting (IPTW) were included, with a propensity score-matched cohort included for sensitivity analyses. Data were analyzed between July 10 and September 8, 2025. Male vs female sex. Overall, liver-related, and non-liver-related mortality. Among 8594 patients with HCC (mean [SD] age, 63.3 [10.9] years; 6214 male [72.3%]; 5644 Asian [65.7%], 458 Black [5.3%], 615 Hispanic [7.2%], and 1784 White [20.8%]), 4567 were from Asia (53.1%), 6327 had cirrhosis (73.6%), and 6617 had viral etiology (77.0%). In the unmatched cohort, males had a higher overall mortality rate per 100 person-years than females in the total cohort (15.9 [95% CI, 15.3-16.4] vs 13.3 [95% CI, 12.5-14.1]; P < .001) and in Asian (14.1 [95% CI, 13.5-14.7] vs 11.1 [95% CI, 10.3-12.0]; P < .001), Asia region (14.4 [95% CI, 13.6-15.2] vs 10.8 [95% CI, 9.9-11.8]; P < .001), cirrhosis (17.6 [95% CI, 16.9-18.3] vs 14.4 [95% CI, 13.5-15.4]; P < .001), and hepatitis B (13.6 [95% CI, 12.7-14.5] vs 10.0 [95% CI, 8.6-11.5]; P < .001) and C (15.8 [95% CI, 15.0-16.6] vs 13.4 [95% CI, 12.4-14.6]; P < .001) subgroups. In the IPTW-matched cohort, male sex was associated with increased overall mortality in the full cohort (adjusted hazard ratio [aHR], 1.14 [95% CI, 1.05-1.23]; P = .002) and in Asian (aHR, 1.22 [95% CI, 1.10-1.36]; P < .001), Asia region (aHR, 1.23 [95% CI, 1.09-1.39]; P < .001), cirrhosis (aHR, 1.18 [95% CI, 1.08-1.29]; P < .001), and viral (aHR, 1.15 [95% CI, 1.05-1.26]; P = .004) subgroups. Additionally, sex differences varied by liver disease etiology, with male sex having the highest aHR in the association with overall mortality among individuals with alcohol-associated liver disease (aHR, 1.90 [95% CI, 1.02-3.54]; P = .04), followed by those with hepatitis B (aHR, 1.22 [95% CI, 1.01-1.47]; P = .04) or C (aHR, 1.13 [95% CI, 1.02-1.26]; P = .03), but there was no association in patients with metabolic dysfunction-associated steatotic liver disease. There was no significant sex difference for non-liver-related mortality. In this study, sex disparities in HCC mortality existed but were heterogeneous across ethnic background and liver disease etiologies. These findings support incorporation of sex-based considerations in HCC management.
中文摘要:性别是公认与肝细胞癌(HCC)发病率相关的因素,但其与死亡率的关系尚不清楚。旨在评估性别与HCC患者全因、肝相关和非肝相关死亡风险之间的关系。这项回顾性队列研究纳入来自5个国家和地区17个中心的HCC患者(2000-2023年)。纳入通过逆概率治疗加权(IPTW)使基线特征均衡的男性和女性HCC患者,并纳入倾向评分匹配队列进行敏感性分析。数据分析于2025年7月10日至9月8日进行。暴露为男性与女性。结局为全因、肝相关和非肝相关死亡率。在8594例HCC患者中(平均[SD]年龄63.3[10.9]岁;男性6214例[72.3%];亚裔5644例[65.7%]、黑人458例[5.3%]、西班牙裔615例[7.2%]、白人1784例[20.8%]),4567例来自亚洲(53.1%),6327例有肝硬化(73.6%),6617例为病毒性病因(77.0%)。在未匹配队列中,男性在全队列中的总体死亡率(每100人年)高于女性(15.9[95%CI,15.3-16.4] vs 13.3[95%CI,12.5-14.1];P<.001),在亚裔(14.1[95%CI,13.5-14.7] vs 11.1[95%CI,10.3-12.0];P<.001)、亚洲地区(14.4[95%CI,13.6-15.2] vs 10.8[95%CI,9.9-11.8];P<.001)、肝硬化(17.6[95%CI,16.9-18.3] vs 14.4[95%CI,13.5-15.4];P<.001)以及乙型肝炎(13.6[95%CI,12.7-14.5] vs 10.0[95%CI,8.6-11.5];P<.001)和丙型肝炎(15.8[95%CI,15.0-16.6] vs 13.4[95%CI,12.4-14.6];P<.001)亚组中亦然。在IPTW匹配队列中,男性与全队列总体死亡率增加相关(校正风险比[aHR],1.14[95%CI,1.05-1.23];P=.002),在亚裔(aHR,1.22[95%CI,1.10-1.36];P<.001)、亚洲地区(aHR,1.23[95%CI,1.09-1.39];P<.001)、肝硬化(aHR,1.18[95%CI,1.08-1.29];P<.001)和病毒性(aHR,1.15[95%CI,1.05-1.26];P=.004)亚组中亦然。此外,性别差异因肝病病因不同而异,在酒精相关性肝病患者中,男性与总体死亡率关联的aHR最高(aHR,1.90[95%CI,1.02-3.54];P=.04),其次为乙型肝炎(aHR,1.22[95%CI,1.01-1.47];P=.04)或丙型肝炎(aHR,1.13[95%CI,1.02-1.26];P=.03),但在代谢功能障碍相关脂肪性肝病患者中无关联。非肝相关死亡率无显著性别差异。在本研究中,HCC死亡率的性别差异存在,但在不同种族背景和肝病病因间具有异质性。这些发现支持在HCC管理中纳入基于性别的考量。
13肠道运动障碍 (1篇)
基础研究 (1篇)
Gut dysmotility is a common long-term effect of enterotoxigenic Bacteroides fragilis (ETBF) colonization but the underlying mechanisms are not clear. Here, using mouse colonization models, we found that ETBF-secreted B. fragilis toxin (BFT) causes loss of colonic myenteric neurons, which are crucial regulators of intestinal motility. BFT induced apoptosis in these neurons through the NOD1-RIPK2-CASP9-CASP3 pathway, leading to gut dysmotility that persisted even after the clearance of ETBF. Analyses of human inflammatory bowel disease and colorectal cancer patient cohorts showed a positive correlation between ETBF and Fusobacterium nucleatum abundance. In mice, F. nucleatum-derived 2-hydroxybutyric acid enhanced BFT production in ETBF by alleviating RprY-mediated suppression and aggravated neurotoxicity and dysmotility. This enteric neuron loss and dysmotility enhanced susceptibility to dextran sulfate sodium-induced colitis in mice. Therapeutically, a Bifidobacterium-based probiotic attenuated neuron toxicity and improved intestinal motility. Our findings reveal bacterial interactions regulating intestinal function and a potential clinical therapeutic approach to preventing outcomes of ETBF colonization.
中文摘要:肠道运动障碍是产肠毒素脆弱拟杆菌(ETBF)定植常见的长期效应,但其潜在机制尚不清楚。在此,我们利用小鼠定植模型发现,ETBF分泌的脆弱拟杆菌毒素(BFT)导致结肠肌间神经元丢失,而这些神经元是肠道运动的关键调节因子。BFT通过NOD1-RIPK2-CASP9-CASP3通路诱导这些神经元凋亡,导致即使在ETBF被清除后仍持续存在的肠道运动障碍。对人类炎症性肠病和结直肠癌患者队列的分析显示,ETBF与具核梭杆菌丰度呈正相关。在小鼠中,具核梭杆菌来源的2-羟基丁酸通过减轻RprY介导的抑制来增强ETBF的BFT产生,并加重神经毒性和运动障碍。这种肠神经元丢失和运动障碍增强了小鼠对葡聚糖硫酸钠诱导结肠炎的易感性。在治疗方面,基于双歧杆菌的益生菌减轻了神经元毒性并改善了肠道运动。我们的发现揭示了调节肠道功能的细菌相互作用,以及一种预防ETBF定植后果的潜在临床治疗策略。
14自免肝病 (1篇)
基础研究 (1篇)
Autoimmune liver diseases (AILDs), including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and IgG4-related sclerosing cholangitis, are characterised by immune dysregulation that adversely affects the hepatocytes or bile ducts. Regulatory T cells (Tregs), which are pivotal for immune tolerance, display altered function and abundance across these disorders, with notable differences between peripheral and hepatic environments. This review synthesises current evidence on disease-specific Treg alterations across AILDs, integrating findings from human studies and preclinical models. We highlight heterogeneity in Treg abundance, phenotype and function across disease subtypes, stages and tissue compartments, while examining the influence of the local immune microenvironment and gut-liver axis on Treg stability and function. We further evaluate current and emerging Treg-targeted therapeutic strategies, ranging from restoration of Treg abundance and function to disease-specific modulation of Treg responses, together with the major challenges to their clinical translation. By integrating these findings, we provide a disease-dependent and context-dependent framework for understanding Treg dysregulation in AILDs and identify key priorities for future mechanistic and translational research.
中文摘要:自身免疫性肝病(AILDs),包括自身免疫性肝炎、原发性胆汁性胆管炎、原发性硬化性胆管炎和IgG4相关硬化性胆管炎,以免疫失调为特征,可对肝细胞或胆管造成不良影响。调节性T细胞(Tregs)对免疫耐受至关重要,在这些疾病中其功能与数量均发生改变,且外周与肝脏环境之间存在显著差异。本综述综合了目前关于各AILDs中疾病特异性Treg改变的证据,并整合了人类研究与临床前模型的发现。我们重点阐述了Treg丰度、表型和功能在不同疾病亚型、分期及组织区域间的异质性,同时探讨局部免疫微环境和肠-肝轴对Treg稳定性与功能的影响。我们进一步评估了当前及新兴的Treg靶向治疗策略,涵盖从恢复Treg数量与功能到疾病特异性调节Treg反应,以及其临床转化面临的主要挑战。通过整合这些发现,我们提供了一个疾病依赖性和情境依赖性的框架,用以理解AILDs中的Treg失调,并明确了未来机制研究与转化研究的关键优先事项。
15高甘油三酯血症 (1篇)
临床研究 (1篇)
Managing hypertriglyceridemia (HTG) requires more than lowering triglyceride (TG) levels. Two related but clinically distinct risk domains often guide management: residual atherosclerotic cardiovascular disease (ASCVD) risk and acute pancreatitis (AP) risk. Their relative importance varies among patients and may change over time. Residual ASCVD risk is driven in part by the burden of atherogenic apolipoprotein B (apoB)-containing particles, particularly TG-rich lipoproteins and their cholesterol-enriched remnants, whereas AP risk increases with severe HTG and rises further in extreme HTG, in which chylomicron accumulation, free fatty acid-mediated lipotoxicity, and inflammation contribute to pancreatic injury. Because similar TG values can arise from different combinations of genetic susceptibility, metabolic dysfunction, and other secondary factors, TG alone may not fully characterize clinical risk or provide a sufficient basis for treatment selection. In this review, we examine the genetic and metabolic determinants of HTG and consider how TG, apoB, remnant cholesterol, chylomicronemia, and secondary causes can be integrated into clinical assessment. We also evaluate established treatments and emerging therapies targeting apolipoprotein C-III, angiopoietin-like protein 3, and related pathways. This risk-based framework can help clinicians tailor treatment to each patient's ASCVD and pancreatitis risk profile.
中文摘要:管理高甘油三酯血症(HTG)不仅仅是降低甘油三酯(TG)水平。两个相关但临床不同的风险领域常指导管理:残余动脉粥样硬化性心血管疾病(ASCVD)风险和急性胰腺炎(AP)风险。它们的相对重要性因患者而异,并可能随时间变化。残余ASCVD风险部分由致动脉粥样硬化的含载脂蛋白B(apoB)颗粒负荷驱动,尤其是富含TG的脂蛋白及其富含胆固醇的残粒;而AP风险随严重HTG升高,并在极端HTG中进一步升高,此时乳糜微粒积聚、游离脂肪酸介导的脂毒性和炎症共同促成胰腺损伤。由于相似的TG值可由遗传易感性、代谢功能障碍和其他继发因素的不同组合引起,单凭TG可能无法充分描述临床风险或为治疗选择提供充分依据。在这篇综述中,我们审视HTG的遗传和代谢决定因素,并思考如何将TG、apoB、残粒胆固醇、乳糜微粒血症和继发原因整合到临床评估中。我们还评估针对载脂蛋白C-III、血管生成素样蛋白3及相关通路的成熟治疗和新兴疗法。这种基于风险的框架可帮助临床医生根据每位患者的ASCVD和胰腺炎风险特征制定个体化治疗。
16抗衰老 (1篇)
基础研究 (1篇)
Aging is a complex, irreversible physiological process characterized by gradual deterioration of tissue structure and function, accompanied by impaired regenerative capacity, dysregulated immune homeostasis, and increased susceptibility to chronic age-related diseases (e.g., neurodegenerative disorders, metabolic syndromes, age-related skin lesions, and inflammatory bowel disease). In recent years, plant-derived extracellular vesicles (PDEVs), the lipid bilayer membrane vesicles released by plant cells, have emerged as innovative candidates for anti-aging therapy because of their inherent biocompatibility, safety, and sustainable sourcing advantages. These nanoscale particles contain proteins, lipids, and nucleic acids. Emerging evidence from in vitro and rodent in vivo models has indicated that PDEVs can effectively delay age-related phenotypes and alleviate pathological changes through multiple mechanisms, such as scavenging reactive oxygen species to mitigate oxidative damage, regulating the immune microenvironment to suppress chronic inflammation, modulating gut microbiota composition to restore intestinal homeostasis, and promoting tissue regeneration (a core application in regenerative medicine) by activating stem cell function and repairing damaged tissues. Additionally, PDEVs offer unique potential as natural or engineered cargo-carriers for drug loading and delivery. This review outlines the biogenesis, composition, isolation, characterization, and storage strategies for PDEVs. Furthermore, we systematically summarize advances in the biological functions of PDEVs and their therapeutic applications in various age-related diseases. Finally, we discuss current challenges and future prospects for PDEVs in clinical translation. We hope this work provides valuable insights for advanced research and potential applications of PDEVs in the management of aging and age-related diseases.
中文摘要:衰老是一个复杂且不可逆的生理过程,其特征是组织结构与功能逐渐退化,并伴有再生能力受损、免疫稳态失调以及罹患慢性年龄相关疾病(例如神经退行性疾病、代谢综合征、年龄相关皮肤病变和炎症性肠病)的易感性增加。近年来,植物来源细胞外囊泡(PDEVs)——由植物细胞释放的脂双层膜囊泡——因其固有的生物相容性、安全性及可持续来源优势,已成为抗衰老治疗的创新候选者。这些纳米级颗粒含有蛋白质、脂质和核酸。来自体外和啮齿动物体内模型的新兴证据表明,PDEVs可通过多种机制有效延缓年龄相关表型并减轻病理改变,例如清除活性氧以减轻氧化损伤、调节免疫微环境以抑制慢性炎症、调控肠道菌群组成以恢复肠道稳态,以及通过激活干细胞功能和修复受损组织来促进组织再生(这是再生医学中的核心应用)。此外,PDEVs作为天然或工程化货物载体,在药物装载和递送方面具有独特潜力。本综述概述了PDEVs的生物发生、组成、分离、表征和储存策略。此外,我们系统总结了PDEVs生物学功能进展及其在多种年龄相关疾病中的治疗应用。最后,我们讨论了PDEVs在临床转化中的当前挑战和未来前景。我们希望这项工作为PDEVs在衰老和年龄相关疾病管理中的深入研究和潜在应用提供有价值的见解。
17原发性肝癌 (1篇)
临床研究 (1篇)
During the 21st century, the global burden of primary liver cancer has continued to rise, with the absolute numbers of incident cases and deaths increasing by 59.4% and 55.8%, respectively, between 2000 and 2023. Analysis of the GBD 2023 database shows that although age-standardised incidence and mortality rates declined from 2000, this favourable trend reversed around 2020, highlighting the need for continued surveillance. Viral hepatitis remains the leading cause of primary liver cancer worldwide, but its proportional contribution is decreasing. Notably, despite earlier gains from vaccination and antiviral therapies, hepatitis B- and hepatitis C-associated liver cancer incidence and mortality have rebounded globally since 2020. In contrast, metabolic dysfunction-associated steatotic liver disease has exhibited the fastest growth, with sustained increases in age-adjusted incidence and mortality across regions. Marked geographical variation persists in underlying aetiologies, with hepatitis B predominant in East Asia and Sub-Saharan Africa, hepatitis C in the Middle East, North Africa, the Americas, and alcohol-related disease in Europe and Australasia. Additionally, rising incidence and mortality of intrahepatic cholangiocarcinoma underscore the need for dedicated research beyond hepatocellular carcinoma. Collectively, these findings emphasise the urgency of sustained public health and clinical interventions targeting preventable and treatable liver diseases to curb future liver cancer burden.
中文摘要:在21世纪,全球原发性肝癌负担持续上升,2000年至2023年间,新发病例和死亡病例的绝对数分别增加了59.4%和55.8%。对GBD 2023数据库的分析显示,尽管年龄标化发病率和死亡率自2000年以来有所下降,但这一有利趋势在2020年前后发生逆转,凸显了持续监测的必要性。病毒性肝炎仍是全球原发性肝癌的主要原因,但其构成比正在下降。值得注意的是,尽管早期从疫苗接种和抗病毒治疗中获益,但自2020年以来,全球乙型肝炎和丙型肝炎相关肝癌的发病率和死亡率出现反弹。相比之下,代谢功能障碍相关脂肪性肝病增长最快,各区域年龄调整发病率和死亡率持续上升。潜在病因仍存在明显地理差异,乙型肝炎在东亚和撒哈拉以南非洲占主导,丙型肝炎在中东、北非和美洲占主导,酒精相关肝病在欧洲和大洋洲占主导。此外,肝内胆管癌发病率和死亡率上升,凸显需要在肝细胞癌之外开展专门研究。总体而言,这些发现强调迫切需要针对可预防和可治疗肝病采取持续的公共卫生和临床干预,以遏制未来的肝癌负担。
18内镜/ESD/ERCP (1篇)
临床研究 (1篇)
ESGE and ESGENA recommend that informed consent for gastrointestinal endoscopic procedures should include consent for sedation and cover best practice as outlined in the ESGE Position Statement for informed consent.Strong recommendation, very low certainty of evidence. ESGE and ESGENA recommend pre-assessment, a specific sedation regimen, and enhanced periprocedural monitoring in high-risk patients undergoing gastrointestinal procedures with sedation, to reduce the risk of sedation-related adverse events.Strong recommendation, very low certainty of evidence. ESGE and ESGENA recommend that pre-assessment, sedation regimen, and periprocedural monitoring should be determined by the complexity (duration, invasiveness) of the endoscopic procedure.Strong recommendation, very low certainty of evidence. ESGE and ESGENA suggest that the management of sedation in patients on glucagon-like peptide-1 receptor agonists should be individualized. Conditional recommendation, very low certainty of evidence. ESGE and ESGENA suggest offering the option of diagnostic colonoscopy and gastroscopy without sedation, based on the patient's and endoscopist's preference.Conditional recommendation, very low certainty of evidence. ESGE and ESGENA recommend that sedation should be provided by a dedicated healthcare professional trained in sedation administration and patient monitoring.Strong recommendation, very low certainty of evidence. ESGE and ESGENA recommend propofol for procedural sedation, as first line, depending on the country's human resources, service framework, and legislation.ESGE and ESGENA recommend midazolam for procedural sedation, in combination with opiates when analgesia is required.Strong recommendation, very low certainty of evidence. ESGE and ESGENA suggest the provision of the ultrashort-acting sedative remimazolam in elderly patients and patients with cardiovascular and/or respiratory comorbidities.Conditional recommendation, low certainty of evidence. ESGE and ESGENA suggest exercising caution when combining ultrashort-acting sedatives with other sedatives or analgesics.Conditional recommendation, low certainty of evidence. ESGE and ESGENA suggest capnography monitoring for patients undergoing sedated gastrointestinal endoscopy who are at higher risk of hypoxemia.Conditional recommendation, very low certainty of evidence. ESGE and ESGENA recommend that the use of reversal agents should be restricted to managing sedation-analgesia adverse events that do not improve with nonpharmacological intervention.Strong recommendation, very low certainty of evidence. ESGE and ESGENA recommend that patients be monitored after endoscopy by trained and qualified staff until the return of the patient's baseline observations.Strong recommendation, very low certainty of evidence. ESGE and ESGENA suggest using scoring systems and standardized discharge checklists to facilitate patient readiness for discharge. Assessments should include a detailed record of vital signs, pain levels, and psychomotor performance.Conditional recommendation, very low certainty of evidence. ESGE and ESGENA suggest that the performing endoscopist holds the overall medicolegal responsibility for the patient's treatment, including safe recovery, but may delegate the assessment and discharge to trained and qualified personnel based on standardized discharge criteria.Conditional recommendation, very low certainty of evidence. ESGE and ESGENA recommend that patients receive oral and written information regarding the post-endoscopy period. Contact details should be provided for potential delayed complications, emergencies, or readmission.ESGE and ESGENA recommend that patients undergoing sedated endoscopy have an accompanying person at discharge.Strong recommendation, very low certainty of evidence. ESGE and ESGENA recommend performing emergency endoscopy under moderate sedation in hemodynamically stable patients. Alternatively, emergency endoscopy without sedation in cooperative patients is feasible.ESGE and ESGENA recommend sedation administration by an anesthesiology specialist in emergency endoscopy in patients at increased risk of aspiration, or with hemodynamic instability or significant comorbidities.Strong recommendation, very low certainty of evidence. ESGE and ESGENA recommend consultation with anesthetic and obstetric teams involved in the pregnant patient`s care, together with the patient's choice for the appropriateness and choice of sedation during gastrointestinal endoscopy.Strong recommendation, very low certainty of evidence. ESGE and ESGENA recommend improving and expanding educational offerings on sedation strategies and the principles of airway management, using structured training.Strong recommendation, low certainty of evidence. ESGE and ESGENA recommend the development and implementation of a quality improvement program with performance indicators to monitor the quality of sedation practices in gastrointestinal endoscopy.Strong recommendation, very low certainty of evidence. ESGE and ESGENA recommend a rational use of sedatives to reduce the environmental impact of endoscopy.Strong recommendation, moderate certainty of evidence.
中文摘要:ESGE和ESGENA推荐,胃肠道内镜操作的知情同意应包括对镇静的同意,并涵盖ESGE知情同意立场声明中所述的最佳实践。强烈推荐,证据确定性极低。ESGE和ESGENA推荐,对接受镇静下胃肠道操作的高危患者进行预先评估、制定特定镇静方案并加强围操作期监测,以降低镇静相关不良事件风险。强烈推荐,证据确定性极低。ESGE和ESGENA推荐,预先评估、镇静方案和围操作期监测应根据内镜操作的复杂性(持续时间、侵入性)确定。强烈推荐,证据确定性极低。ESGE和ESGENA建议,使用胰高血糖素样肽-1受体激动剂患者的镇静管理应个体化。有条件推荐,证据确定性极低。ESGE和ESGENA建议,根据患者和内镜医师的偏好,提供不镇静进行诊断性结肠镜和胃镜检查的选项。有条件推荐,证据确定性极低。ESGE和ESGENA推荐,镇静应由接受过镇静给药和患者监测培训的专职医疗专业人员提供。强烈推荐,证据确定性极低。ESGE和ESGENA推荐将丙泊酚作为操作镇静的一线药物,具体取决于各国的人力资源、服务框架和法规。ESGE和ESGENA推荐将咪达唑仑用于操作镇静,在需要镇痛时与阿片类药物联合使用。强烈推荐,证据确定性极低。ESGE和ESGENA建议,对老年患者以及伴有心血管和/或呼吸系统合并症的患者,提供超短效镇静剂瑞马唑仑。有条件推荐,证据确定性低。ESGE和ESGENA建议,将超短效镇静剂与其他镇静剂或镇痛剂联合使用时应谨慎。有条件推荐,证据确定性低。ESGE和ESGENA建议,对接受镇静胃肠道内镜检查且低氧血症风险较高的患者进行二氧化碳图监测。有条件推荐,证据确定性极低。ESGE和ESGENA推荐,逆转剂的使用应限于处理非药物干预后未见改善的镇静-镇痛不良事件。强烈推荐,证据确定性极低。ESGE和ESGENA推荐,内镜检查后应由受过培训且合格的人员对患者进行监测,直至患者恢复到基线观察指标。强烈推荐,证据确定性极低。ESGE和ESGENA建议使用评分系统和标准化离院核对表来促进患者达到离院准备状态。评估应包括生命体征、疼痛程度和精神运动表现的详细记录。有条件推荐,证据确定性极低。ESGE和ESGENA建议,实施操作的内镜医师对患者的治疗承担总体医疗法律责任,包括安全恢复,但可根据标准化离院标准将评估和离院交由受过培训且合格的人员完成。有条件推荐,证据确定性极低。ESGE和ESGENA推荐,患者应获得关于内镜检查后时期的口头和书面信息。应提供联系方式,以应对可能发生的延迟并发症、紧急情况或再入院。ESGE和ESGENA推荐,接受镇静内镜检查的患者在离院时应有陪同人员。强烈推荐,证据确定性极低。ESGE和ESGENA推荐,对血流动力学稳定的患者在中等镇静下进行急诊内镜。或者,对配合的患者不镇静进行急诊内镜是可行的。ESGE和ESGENA推荐,对误吸风险增加、或血流动力学不稳定或伴有显著合并症的患者,在急诊内镜中由麻醉专科医师实施镇静。强烈推荐,证据确定性极低。ESGE和ESGENA推荐,就胃肠道内镜检查期间镇静的适当性和选择,与参与妊娠患者照护的麻醉团队和产科团队进行会诊,并结合患者的选择。强烈推荐,证据确定性极低。ESGE和ESGENA推荐,通过结构化培训改进和扩展关于镇静策略及气道管理原则的教育课程。强烈推荐,证据确定性低。ESGE和ESGENA推荐,制定并实施包含绩效指标的质量改进计划,以监测胃肠道内镜镇静实践的质量。强烈推荐,证据确定性极低。ESGE和ESGENA推荐合理使用镇静剂,以减少内镜对环境的影响。强烈推荐,证据确定性中等。
19肝癌筛查 (1篇)
临床研究 (1篇)
Liver cancer surveillance is supported by a strong rationale and observational research; however, evidence from randomised trials is lacking, limiting support from organisations beyond hepatology, such as national screening committees. The absence of such trials has been acknowledged in the hepatology community for over 25 years. Screening is often performed in low-prevalence populations, and screening tests are imperfect. As a result, most positive results are false positives. Although novel screening modalities are being investigated to complement or replace ultrasound for liver cancer surveillance, challenges remain, particularly regarding the weak evidence base. The ultimate aim of liver cancer surveillance is to improve survival, but many patients do not experience notable benefits due to low cancer incidence, limited test sensitivity, and competing mortality risks. Implementing risk-based hepatocellular carcinoma surveillance, as recommended by some guidelines, may enhance outcomes by tailoring surveillance to individual patient risk profiles. Many risk prediction models exist, and they have been implemented for patients with chronic hepatitis B. Stronger evidence, persistent advocacy, and consultations with national and international screening committees could pave the way for improved liver cancer surveillance practices.
中文摘要:肝癌监测有充分理由和观察性研究支持;然而,缺乏随机试验证据,限制了肝病学领域以外组织(如国家筛查委员会)的支持。肝病学界承认此类试验缺失已超过25年。筛查常在低患病率人群中进行,且筛查试验并不完美。因此,大多数阳性结果为假阳性。尽管正在研究新型筛查方式以补充或替代超声用于肝癌监测,但挑战依然存在,尤其是证据基础薄弱。肝癌监测的最终目标是提高生存率,但由于癌症发生率低、检测敏感性有限以及竞争性死亡风险,许多患者并未获得显著获益。按照一些指南推荐,实施基于风险的肝细胞癌监测,可能通过根据个体患者风险特征定制监测来改善结局。现有许多风险预测模型,并已用于慢性乙型肝炎患者。更强证据、持续倡导以及与国家和国际筛查委员会的磋商,可能为改进肝癌监测实践铺平道路。
20内镜/ERCP (1篇)
临床研究 (1篇)
Robotic assistance may mitigate occupational hazards associated with endoscopic retrograde cholangiopancreatography (ERCP). We evaluated the safety, feasibility, and learning curve of a new ERCP robotic system. In this observational study, 26 patients with common bile duct stones underwent robotic-assisted ERCP; 6 underwent biliary cannulation only and 20 underwent stone extraction. For the 20 cases with stone extraction, comparisons were performed using 1:1 propensity score matching (PSM) with conventional ERCP performed by the same operator. The safety outcome was adverse events. Feasibility outcomes included technical success, procedural times, operator radiation exposure, and learning-curve characteristics. After PSM, adverse event rates were similar between groups. Post-ERCP pancreatitis occurred in 15.0% (3/20, robotic) and 10.0% (2/20, conventional) (P >0.99), with no bleeding, perforation, or procedure-related mortality. Biliary cannulation and stone extraction success rates were 100% (20/20) in both groups. Robotic-assisted ERCP had a longer procedure time (36.6 vs. 17.0 minutes; P < 0.001), but similar cannulation and fluoroscopy times. In robotic-assisted procedures, radiation exposure was markedly lower in the control room than in the operation room (0.10 vs. 1.26 μSv; P < 0.001). Learning-curve analysis suggested performance stabilization after 10-12 cases. Robotic-assisted ERCP appeared safe and feasible, with high technical success and substantially reduced operator radiation exposure.
中文摘要:机器人辅助可能减轻与经内镜逆行胰胆管造影(ERCP)相关的职业危害。我们评估了一种新型ERCP机器人系统的安全性、可行性和学习曲线。在这项观察性研究中,26例胆总管结石患者接受了机器人辅助ERCP;其中6例仅行胆管插管,20例行取石。对于20例取石病例,使用1:1倾向评分匹配(PSM)与同一操作者实施的传统ERCP进行比较。安全性结局为不良事件。可行性结局包括技术成功、手术时间、操作者辐射暴露和学习曲线特征。PSM后,两组不良事件发生率相似。ERCP术后胰腺炎发生率在机器人组为15.0%(3/20),传统组为10.0%(2/20)(P >0.99),无出血、穿孔或手术相关死亡。两组的胆管插管和取石成功率均为100%(20/20)。机器人辅助ERCP的手术时间更长(36.6分钟 vs. 17.0分钟;P < 0.001),但插管时间和透视时间相似。在机器人辅助操作中,控制室内的辐射暴露明显低于操作室(0.10 μSv vs. 1.26 μSv;P < 0.001)。学习曲线分析提示在10-12例后表现趋于稳定。机器人辅助ERCP似乎安全可行,技术成功率高,并显著降低了操作者辐射暴露。
21肠易激综合征 (1篇)
临床研究 (1篇)
Fecal microbiota transplantation (FMT) could improve symptoms of irritable bowel syndrome (IBS) in some previous trials. We updated a prior meta-analysis of randomized controlled trials (RCTs) determining this issue. We searched CENTRAL, MEDLINE, and Embase (via Ovid) from inception to February 20, 2026, to identify potential studies. We included RCTs that reported the proportion of patients with IBS symptom improvement assessed between 4 and 24 weeks after FMT. For primary outcome, we estimated risk ratios (RR) of proportion of patients with IBS symptoms not improved. Data were pooled using a random effects model. The certainty of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation. Thirteen RCTs involving 693 patients were eligible for this review. For the intention-to-treat analysis, FMT may reduce IBS symptoms at 12 weeks compared with placebo, but the evidence is very uncertain (RR of symptom not improved with FMT compared with placebo = 0.72; 95% confidence interval [CI], 0.50-1.03). However, in the per-protocol analysis, FMT was statistically significant at improving symptoms (RR, 0.67; 95% CI, 0.46-0.97). Overall adverse events were not different in both groups (RR, 0.98; 95% CI, 0.75-1.29). The subgroup analysis reported IBS symptom improvement using a single dose of FMT (RR, 0.62; 95% CI, 0.41-0.93), and when IBS was diagnosed by Rome IV criteria (RR, 0.38; 95% CI, 0.17-0.86). This systematic review suggested there was very low certainty of evidence that FMT improved IBS symptoms. FMT was effective in some subgroup analyses and in the overall per-protocol analysis, but this needs to be interpreted with caution. (Registration number: PROSPERO CRD420251086189.).
中文摘要:粪菌移植(FMT)在一些既往试验中可改善肠易激综合征(IBS)症状。我们更新了此前一项旨在明确该问题的随机对照试验(RCT)荟萃分析。我们检索了CENTRAL、MEDLINE和Embase(通过Ovid),时间从建库至2026年2月20日,以识别潜在研究。我们纳入报告FMT后4至24周评估的IBS症状改善患者比例的RCT。对于主要结局,我们估计了IBS症状未改善患者比例的风险比(RR)。采用随机效应模型汇总数据。使用推荐分级的评估、制定与评价(GRADE)评估证据确定性。13项RCT共693例患者符合本综述纳入标准。在意向性治疗分析中,与安慰剂相比,FMT可能减轻12周时的IBS症状,但证据非常不确定(FMT与安慰剂相比症状未改善的RR=0.72;95%置信区间[CI],0.50-1.03)。然而,在符合方案分析中,FMT在改善症状方面具有统计学显著性(RR,0.67;95%CI,0.46-0.97)。两组总体不良事件无差异(RR,0.98;95%CI,0.75-1.29)。亚组分析报告,使用单次剂量FMT时IBS症状改善(RR,0.62;95%CI,0.41-0.93),并且在IBS由罗马IV标准诊断时也显示改善(RR,0.38;95%CI,0.17-0.86)。本系统综述提示,FMT改善IBS症状的证据确定性极低。FMT在一些亚组分析和总体符合方案分析中有效,但需谨慎解读。(注册号:PROSPERO CRD420251086189。)